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Abstract 
Background: A Westernised lifestyle, which involves a high-energy diet and reduced 
physical activity, is indisputably linked to the pandemics of obesity and type 2 
diabetes. Prevention of cardiovascular disease and type 2 diabetes is a public health 
goal. Intake of fish has been associated with reduced risk of cardiovascular disease, 
but data from randomized controlled trials have been inconclusive. Lean fish contains 
relatively low amount of marine omega-3 fatty acids, and data from both animal and 
human studies indicate a beneficial effects on lipid metabolism, insulin sensitivity 
and glucose homeostasis. Studies investigating the potential protective effect of lean-
seafood in healthy subjects are warranted.    
Aim: The overall aim of this thesis was to elucidate how lean-seafood can modulate 
fasting and postprandial metabolism of lipids and glucose in healthy humans. 
Subjects and Methods: Healthy Caucasian subjects were recruited from the great 
area of Bergen. The study included two 4-weeks experimental periods separated by a 
5-weeks washout period in a crossover design. Prior to each experimental period, the 
subjects followed a diet in accordance with the Norwegian dietary recommendations 
for 3 weeks run-in periods. Half of the group (6 men and 8 women) was randomly 
assigned to begin with a lean-seafood diet and the other group (4 men and 9 women) 
to a nonseafood diet. The lean-seafood diet consisted of lunch- and dinner meals with 
cod, pollack, saithe and scallops and the nonseafood diet contained skinless chicken 
filet, lean beef, turkey, pork, egg, milk and milk products. The protein contribution 
from the experimental protein sources in both diets corresponded to 60 % of total 
protein intake, and the remaining dietary proteins came from vegetable and cereal 
sources. 
Results: Healthy subjects had after 4 weeks lean-seafood intervention, a highly 
significant reduction in fasting and postprandial circulating TAG concentrations, 
relative to the 4 weeks nonseafood intervention. There is evidence that raised 
circulating TAG levels are associated with increased coronary heart disease risk. The 
TAG/ HDL-cholesterol ratio was decreased during the lean-seafood intervention and 
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increased during the nonseafood intervention. The intervention did not alter fasting 
and postprandial serum glucose or insulin concentration. However, lean-seafood 
intake reduced postprandial C-peptide and lactate concentrations.  Lean-seafood 
intake improved mitochondrial oxidative capacity as indicated by human urinary 
metabolomics. All results are consistent, indicating an improved preservation of 
insulin-sensitivity after lean-seafood consumption. 
Conclusion: Based on our data lean-seafood regulates fasting and postprandial lipids 
and glucose metabolism differently in healthy subjects after four weeks. Lean-
seafood modulate fasting and postprandial lipids, and postprandial glucose 
metabolism in healthy individuals in a manner that may have an effect on the long-
term development of cardiovascular disease, insulin-resistance and type 2 diabetes. 
An increased intake of lean-seafood should be encouraged as a part of a healthy diet 
in the prevention of CVD and T2D, and therefore may have a part of combating the 
development of these health challenges.  
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1. Introduction 
1.1 The global strategy on diet and health  
The global burden of non-communicable diseases (NCD) increases and is the biggest 
cause of deaths worldwide. More than 36 million people die annually from NCDs (63% 
of global deaths), including 14 million people before the age of 70. More than 90% of 
these deaths from NCDs occur in low- and middle-income countries (WHO 2013). The 
burden of mortality, morbidity and disability attributable to chronic disease problem is 
far from being limited to the developing countries. Chronic diseases are emerging both 
in poorer countries and in poorer population groups in developed countries (WHO 
2004; Lozano et al. 2012).  
For all countries, the underlying behavioural factors are largely the same. An elevated 
consumption of energy-dense, nutrient-poor foods that are high in fat, sugar and salt 
combined with reduced levels of physical activity are the main factors that increase the 
major chronic diseases (WHO 2004). The burden of diet-related chronic diseases is 
attributable to cardiovascular diseases mainly. Obesity and diabetes are also showing 
worrying trends, not only because they already affect a large proportion of the 
population, but also because they appear earlier in life. Chronic diseases are largely 
preventable diseases. The public health approach of primary prevention is considered 
to be the most cost-effective, affordable and sustainable course of action to cope with 
the chronic disease epidemic worldwide (WHO 2013; Ryden et al. 2007). 
A Westernised lifestyle, which involves a high-energy diet and reduced physical 
activity, is indisputably linked to the pandemics of obesity and type 2 diabetes (Nolan 
et al. 2011). A meta-analysis of 102 prospective studies (almost 700 000 people) 
without previous vascular disease from the Emerging Risk Factors Collaboration 
provides information about the relation between glucose concentrations, diabetes 
status, and cardiovascular outcomes. The analysis showed that diabetes confers about 
a two-fold excess risk for coronary heart disease, major stroke subtypes, and deaths 
attributed to other vascular causes (Sarwar et al. 2010). Almost 4 of 5 cases of 
myocardial infarction in healthy men may be prevented with low-risk behaviour like; 
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healthy diet consumption, moderate alcohol consumption, no smoking, being 
physically active and having a healthy body weight. A healthy diet can prevent 1 of 5 
myocardial infarction alone (Åkesson et al. 2014). 
 
1.2 Healthy diets 
The Mediterranean diet has been reported to be a model of healthy eating for its 
contribution to a favourable health status. A traditional Mediterranean diet is rich in 
bread, root- and green vegetables, fruit, oil (high in linoleic acid) and fish, and low in 
meat, butter and cream. A Mediterranean diet is associated with decreased 
cardiovascular risk (Sofi et al. 2008) and are shown to prevent secondary 
cardiovascular disease (CVD) (de Lorgeril et al. 1994; 1996; 1999). The protective 
effect of the Mediterranean dietary pattern was maintained for up to four years after 
the first myocardial infarction (de Lorgeril et al. 1999). In high cardiovascular risk 
subjects, intake of the Mediterranean diet, supplemented with extra-virgin olive oil or 
mixed nuts, resulted in a substantial reduction in the incidence of major cardiovascular 
events (Estruch et al. 2013). In this primary prevention trial Estruch et al. (2013) 
suggested a potentially greater benefit of the Mediterranean diet as compared with 
Western diets.  
Differences in food cultures, limited accessibility to local resources and ecological 
aspect may hamper other populations, such as Scandinavians, from consuming a 
Mediterranean-like diet (Papadaki & Scott 2002). An alternative to the Mediterranean 
diet is the regional Nordic diet, using foods naturally grown in the Nordic countries, 
such as apples and berries, rye, rapeseed oil, salmon, roots, cabbages, peas, and dairy 
products; furthermore, the long coastlines provides rich sources of fish (Bere & Brug 
2009). Intake of a healthy Nordic diet improved lipid profiles and insulin sensitivity, 
and decreased body weight and blood pressure in 88 Swedish hypercholesterolaemic 
subjects (Adamsson et al. 2011; Uusitupa et al. 2013). These results are in agreement 
with those of a controlled study conducted in 131 pre-diabetic Finnish participants 
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suggesting an improved glucose metabolism after consumption of a Nordic diet 
(Lankinen et al. 2011).  
Behind all healthy diets, there is the concept of change of the usual diet towards a 
healthy dietary pattern using local and seasonal products. Development of country-
specific guidelines is needed to provide practical educational instruments, which 
consider variation in dietary patterns, accessibility to foods, and agriculture in different 
regions globally (Ryden et al. 2007; Paulweber et al. 2010; Ley et al. 2014).  
 
1.2.1 National dietary guidelines and food consumption in Norway 
The Norwegian dietary recommendations (The Norwegian Directorate of Health 2014) 
are based on the Nordic Nutrition Recommendations 2012 published by The Nordic 
Council of Ministers (2014) and have a main focus to prevent chronic diet-related 
diseases in the population. The recommendations are directed primarily towards 
healthy adult subjects with normal levels of physical activity since the research that 
forms the knowledge base, is performed on this part of the population mainly (The 
Norwegian Directorate of Health 2011). The diet recommendations are based on foods 
and food cultures that are common in Norway. A healthy diet should be predominantly 
plant based and containing vegetables, fruits, berries, whole grains and fish. It is 
recommended to achieve energy balance and a healthy weight. Moreover, it is 
recommended to limit the intake of salt, added sugars, and energy intake from total 
fats, and to shift fat consumption from saturated fats (SFA) to unsaturated fats (The 
Norwegian Directorate of Health 2011; WHO 2013). 
The daily average intake of salt in Norway is estimated to be around 10 grams per 
person. This is twice as high as recommended. Processed food and pre-prepared meals 
contributes to a large extent to the salt intake in the population. The consumption of 
sugar has decreased the last ten years. Today, added sugar contributes to 13 % of the 
daily energy intake, but is still higher than the recommended level of less than 10% of 
the daily energy intake (Totland et al. 2012). The average Norwegian population 
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spends three times as much money on sweets and soft drinks as on fish (The Norwegian 
Directorate of Health 2015).  
The amount of fruits, vegetables and berries should be at least 500 gram per day, 
approximately half of the amount should be vegetables and the other half should consist 
of fruits and berries. Most individuals eat less than recommended (The Norwegian 
Directorate of Health 2011). The recommended intake of vegetables of at least 250 
gram per day was achieved by about 15 % of men and women (Totland et al. 2012). It 
is desirable to have an increase in vegetable consumption (The Norwegian Directorate 
of Health 2015). The recommendation of four servings of whole grain products per day 
is equivalent to approximately 70-90 gram whole grains per day. The average intake of 
whole grains in the Norwegian population is estimated to be approximately 50 gram 
per day. Probably a large percentage of the population is therefore eating significantly 
less than the recommendations (The Norwegian Directorate of Health 2011). The 
recommended amount of two to three servings of fish for dinner and some servings of 
fish as spread per week, is equivalent to 300-450 grams per week. Both lean and fatty 
fish should be included, but at least 200 gram of fatty fish is recommended per week. 
In the national dietary survey Norkost 3, from 2010-11, the average intake of fish is 
310 grams a week for women and 450 grams a week for men. From the average intake, 
lean fish contributed most with 60 percent of the total fish consumption, while fatty 
fish contributed with 40 percent. About half of the Norwegian population eats less fish 
than the national dietary recommendation. Among women it was 31 percent and among 
men it was 39 percent, who consumed more than 375 grams fish per week. In pregnant 
women the average total fish intake was 217 grams a week, and lower than the average 
women (Totland et al. 2012). The consumption of fish in Norway has been stable for 
the past ten years, but it is lower than desirable and substantially lower than the 
consumption of meat (560 gram per week) (The Norwegian Directorate of Health 
2015). 
In spite of several positive trends in food consumption in recent years, large parts of 
the Norwegian population have a diet with significant nutritional weaknesses that may 
contribute to the development of cardiovascular diseases, cancers, obesity, type 2 
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diabetes, constipation, tooth decay and iron deficiency. Adopting the Norwegian 
Directorate of Health’s recommendations for a healthy diet and physical activity is 
likely to reduce the incidence of these diseases (The Norwegian Directorate of Health 
2015).  
 
1.3 Seafood consumption and prevention of cardiovascular diseases 
An important component of a healthy dietary pattern is fish. During the last two 
decades, several epidemiological studies and clinical trials have indicated the beneficial 
effects of fish intake in the primary and secondary prevention of several diseases, 
including CVD. CVD is a collective term for conditions that affect the whole blood 
circulatory system, ie, the heart and blood vessels (The Norwegian Directorate of 
Health 2011). A large number of prospective studies have shown that regular fish 
consumption is related to a lower risk of CVD such as stroke (He et al. 2004a) and 
coronary heart disease (CHD) (He et al. 2004b). The health promoting effect of fish 
has primarily been ascribed to the long-chain n-3 polyunsaturated fatty acids (n-3 
PUFA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (Dyerberg et 
al. 1978). A meta-analysis of randomised intervention trials showed that n-3 PUFA 
significantly reduced deaths from cardiac causes in patients with CHD (Leon et al. 
2008). Even though some of the cardioprotective effects of fish consumption could be 
ascribed to marine n-3 fatty acids (Mozaffarian & Wu 2011), one study showed that 
intake of as little as one or two dishes of lean fish a week, which contains relatively 
low amounts of marine n-3 fatty acids, was also inversely associated with CHD 
mortality (Kromhout et al. 1985). 
The protein moiety in fish is also considered to have positive effects in relation to 
lifestyle-related diseases. The 26-year follow up Nurses` Health Study demonstrated a 
significant association between intake and outcome in risk of coronary heart disease 
from choosing fish, poultry, nuts and low fat dairy as major dietary protein source, 
compared to red meat and high-fat dairy (Bernstein et al. 2010).  
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Lean fish intake, whose major constituent is fish protein, has induced lower total 
cholesterol and triacylglycerol (TAG) concentrations in human subjects (Gunnarsdottir 
et al. 2008). In normolipidemic (Lacaille et al. 2000) and hypercholesterolemic 
(Beauchesne-Rondeau et al. 2003) men, lean fish intake provoked an increase of high-
density lipoprotein (HDL), mainly as HDL2, the cardioprotective lipoprotein fraction. 
The effects of lean fish consumption have been examined in premenopausal (Gascon 
et al. 1996) and postmenopausal (Jacques et al. 1992) women given well-controlled 
low-fat (30%), high PUFA:SFA (1:1) ratio diets. In these studies, intake of lean fish 
induced a lower plasma TAG concentration and higher concentrations of low-density 
lipoprotein (LDL) - apolipoprotein B (apo B) in plasma than other animal protein 
sources. In postmenopausal women, lean fish, compared with other animal protein 
sources, induced higher concentrations of plasma total and HDL cholesterol (Jacques 
et al. 1992). However, those studies have been conducted in human subjects in the 
fasting state only. In keeping with the fact that development of atherogenesis might be 
a postprandial phenomenon (Zilversmit 1979), postprandial studies is warranted. The 
three prospective studies, the Women`s Health Study (Bansal et al. 2007), the 
Norwegian Counties Study (Lindman et al. 2010) and the Copenhagen City Heart 
Study (Nordestgaard et al. 2007) have confirmed the association of postprandial TAG 
as a risk factor for CVD. Non-fasting lipid concentration might be a better indicator of 
average lipid concentrations in the blood rather than fasting concentrations 
(Nordestgaard & Varbo 2014). Furthermore, most people spend the majority of the day 
in the postprandial state.  
 
1.3.1 Lipid metabolism 
A healthy diet consist of all three major macronutrients: protein, carbohydrate and 
lipids. Over 95% of dietary lipids are TAGs, the rest are phospholipids, free fatty acids 
(FFAs), cholesterol (present in foods as free and esterified cholesterol), and fat-soluble 
vitamins. In the cells of the small intestine dietary TAG are packed with cholesterol 
and phospholipids into chylomicrons (CM), the largest of the lipoprotein-particles. The 
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CM particles also contain one apolipoprotein B48 (apoB48) as a structural protein. 
Ninety % of the chylomicron TAG is converted to fatty acids and glycerol, which are 
taken up by adipocytes and muscle cells for energy use or storage. After fat ingestion 
the concentration of CM in the blood increases transiently, as these particles have 
relatively short half-life in healthy subjects, approximately 5 min (Grundy & Mok 
1976). Cholesterol-rich chylomicron remnants are taken up by the liver. Very low 
density lipoprotein (VLDL) particles are secreted continuously from the liver, for 
delivery of TAG in the postprandial state. In contrast to CM and chylomicron remnants, 
VLDL are characterized by their apoB100 content. The secretion of VLDL is under 
complex regulation, as secretion of the larger and more TAG-rich VLDL species are 
repressed by insulin signaling (Malmström et al. 1997; Adiels et al. 2007; Adiels et al. 
2008). In circulation, the VLDL are converted to intermediate-density lipoprotein 
(IDL) and then further to LDL by lipoprotein lipase. LDL are depleted of TAGs, 
phospholipids and are enriched in cholesteryl esters. The LDL particles bind to LDL 
receptors on all cells, and the entire particle is taken up by the cells. Once inside the 
cell cholesterol can be used to produce steroid hormones or contribute as a structural 
element in the cell membranes. Raised concentrations of LDL cholesterol predisposes 
an individual to cardiovascular disease, and LDL lowering is a prime lipid target 
(Nordestgaard & Varbo 2014). HDL cholesterol is responsible for the removal of 
excess peripheral cholesterol and its return to the liver. HDL receptors in the liver are 
receiving cholesterol esters from HDL, enabling the HDL particle to continue the 
reverse cholesterol transport from peripheral tissues. In the liver cholesterol can be used 
to produce bile acids (Rashid et al. 2003; Tremblay et al. 2007; McQueen et al. 2008). 
Raised TAG concentrations are strongly associated with low concentrations of HDL 
cholesterol (Varbo et al. 2013). An overview of postprandial lipid metabolism are 
outlined in Figure 1.1. 
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Figure 1.1 Simplified flowchart showing the essentials of lipoprotein metabolism. CM = chylomicron, 
LPL = Lipoprotein lipase, VLDL = very low density lipoprotein, IDL = intermediate-density 
lipoprotein, LDL = low density lipoprotein. 
 
1.4 Seafood consumption and prevention of diabetes type 2 
Lifestyle changes that include moderate weight loss and regular physical activity (150 
min/week), with dietary strategies including reduced energy intake and reduced intake 
of dietary fat, may reduce the risk for developing diabetes and are therefore 
recommended as shown in the Diabetes Prevention Program (Knowler et al. 2002; 
Bantle et al. 2008) and in the European evidence-based guideline (Paulweber et al. 
2010). The WHO has estimated that 90% of type 2 diabetes (T2D) can be prevented by 
changes in diet, physical activity and smoking habits (WHO 2013). Several studies 
among people with overweight and impaired glucose tolerance have shown that 
changing dietary and exercise habits in line with current recommendations can prevent 
or reduce the risk of T2D by 40-60% over a period of approximately a decade 
(Tuomilehto et al. 2001; Knowler et al. 2002; Lindstrom et al. 2006). Intake of diets 
rich in whole grains, fruits, vegetables, legumes, nuts and low in refined grains, red or 
processed meats, and sugar-sweetened beverages have been shown to reduce the risk 
of diabetes and to improve glycaemic control and blood lipids in subjects with diabetes 
(Ley et al. 2014). The potential impact of seafood consumption on the development of 
insulin-resistance is yet not fully clarified. A number of prospective studies have 
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explored the association between fish consumption and risk of T2D, with inconclusive 
results. The protective effect from total fish consumption was observed in Japanese 
men, but not in women (Nanri et al. 2011). Lower incidence of T2D was reported in 
Chinese women after consumption of fish (Villegas et al. 2011). Other prospective 
cohort studies reported that a higher fish intake did not prevent T2D (van Woudenbergh 
et al. 2009; Kaushik et al. 2009; Djousse et al. 2012). One difference in the conflicting 
findings between fish consumption and risk of diabetes was reported between 
geographical regions, as meta-analyses of prospective studies conducted in North 
America and Europe indicated an increased risk, while studies performed in Asia 
showed a protective effect of T2D with fish consumption (Xun & He 2012; Wallin et 
al. 2012; Wylie-Rosett et al. 2012). All the above mentioned meta-analyses concluded 
that further investigation is warranted. Some of the discrepancy in the varying 
outcomes from the different prospective cohort studies might be the lack of distinction 
between fatty and lean fish. A recent prospective population based cohort study of 
Norwegian women (NOWAC) showed inverse association between lean fish 
consumption and T2D development. The authors marked that it was unclear whether 
lean fish itself had a protective effect on T2D, or if lean fish consumers have a 
protective life style that was not possible to take into account in the study (Rylander et 
al. 2014). However, it is also likely that some of the discrepancy in the different 
prospective cohort studies is caused by the use of validated semi-quantitative food-
frequency questionnaires that may cause erroneous food intake reporting. Another 
contributing factor to the discrepant results may be the differences in amount of fish 
intake, the different preparation or the cooking methods used in the different locations 
(Mozaffarian et al. 2003; Patel et al. 2012). 
To detect and understand the association between total and type of fish intake and 
insulin-sensitivity, an increasing number of intervention studies have been conducted 
recently. In a test meal-study, healthy women received three test meals with 45 g 
protein either as cod fillet, cottage cheese (milk protein), or soy protein isolate. 
Ingestion of the cod protein meal resulted in lower serum insulin/glucose and insulin/C-
peptide ratios, as compared to the cottage cheese meal, suggesting that different protein 
sources affect glucose and insulin metabolism differently (von Post-Skagegard et al. 
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2006). In a 4 week intervention study with cross-over design, dietary cod protein, as 
compared to a similar diet containing lean beef, pork, veal, eggs, milk, and milk 
products, improved the insulin sensitivity in insulin-resistant individuals and thus could 
contribute to prevention of type 2 diabetes by reducing the metabolic complications 
related to insulin resistance (Ouellet et al. 2007). From the same study, a reduced 
plasma concentration of the systemic inflammation marker C-reactive protein (CRP) 
was reported (Ouellet et al. 2008). The underlying mechanism to the improved insulin-
sensitivity by lean fish intake remains to be completely elucidated. However, from 
studies with rats fed a high-sucrose diet, both cod and soy proteins reduced fasting and 
postprandial glucose and insulin responses and increased peripheral insulin sensitivity 
compared with casein (Lavigne et al. 2000). In follow-up studies cod protein feeding, 
as compared to soy protein and casein, prevented rats from developing skeletal muscle 
insulin-resistance (Lavigne et al. 2001). In support of these studies, a free-living 
randomized study with overweight adults receiving capsules with cod protein or 
placebo for 8 weeks improved glucose homeostasis and favorably altered body 
composition in the participants (Vikoren et al. 2013). Human studies exploring the 
association between seafood consumption and risk of T2D have previously only been 
conducted among overweight or insulin-resistant individuals given single nutrient or a 
single meal.  
 
1.4.1 Fasting and postprandial glucose metabolism in healthy subjects 
In the fasting state the blood glucose concentration is maintained by endogenous 
glucose production, mainly from hepatic glycogenolysis and gluconeogenesis under 
the direction of glucagon among others. The brain cannot synthesize glucose or store 
glycogen, and are therefore dependent on a continuous supply of glucose from plasma 
(Nolan et al. 2011).   
After a meal, blood glucose concentration is transiently elevated, which stimulates 
insulin secretion by islet ß-cells and suppresses glucagon secretion after activation of 
glucagon-like peptide 1 (GLP-1) (Nolan et al. 2011). C-peptide is secreted into the 
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bloodstream in equal quantities to insulin. Since C-peptide has a longer half-life than 
insulin (20 – 30 versus 3-5 minutes), and is commonly used in preference to insulin 
measurement when assessing ß-cell function (Jones & Hattersley 2013). GLP-1 is an 
incretin hormone, which increases glucose-stimulated insulin secretion and glucose-
suppression of glucagon secretion. At the same time endogenous glucose production is 
suppressed, which helps to curtail total glucose input into blood. Glucose uptake into 
insulin-sensitive peripheral tissues, such as skeletal muscle and adipose tissue is 
activated (Nolan et al. 2011). The splanchnic bed (liver and gut), the skeletal muscles, 
and the non-insulin responsive tissues (in particular the brain) each dispose of ~ 1/3 of 
the ingested glucose (Kelley et al. 1988; Woerle et al. 2003; Moore et al. 2003; Nolan 
et al. 2011). Majority of the postprandial glucose taken up by the liver is stored as 
glycogen (Kelley et al. 1988). In healthy subjects, direct glucose storage accounted for 
33% and glycolysis for 67% of the total disposal during the postprandial period. Most 
of the glucose is oxidized (43.5 %) and about 23.5 % undergoes non-oxidative 
glycolysis (Woerle et al. 2003). Hence, the ability of the liver to store glucose as 
glycogen after a mix meal, with subsequent release of hepatic glucose from glycogen 
in the post absorptive phase is important for normal glucose homeostasis in healthy 
subjects (Nolan et al. 2011). An overview of fasting and postprandial glucose 
metabolism in healthy subjects are outlined in Figure 1.2. 
Lactate metabolism is profoundly related to glucose metabolism, as lactate formation 
is believed to arise from pyruvate as part of glycolysis (Garcia-Alvarez et al. 2014).  
Glucose is one of the most important sources of lactate while lactate is a major substrate 
to synthesize endogenous glucose. In the postabsorptive state, it has been estimated 
that approximately 65 % of the lactate is derived from glucose while 16 – 20 % of the 
lactate stems from alanine (Perriello et al. 1995). When oxidative capacity decreases, 
plasma lactate concentration increases as a consequence of greater flux through 
glycolytic pathways (Del Prato et al. 1993).  
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Figure 1.2 A simplified flowchart showing normal fasting and postprandial glucose metabolism. 
In the fasting state the blood glucose level are decreasing, leading to a low insulin-to-glucagon ratio in 
plasma. Glucagon markedly increase the release of glucose by the liver. The brain in dependent on 
glucose, while the entry of glucose into muscle and adipose tissue decreases in response to a low insulin 
level (A). In the postprandial state the incretin hormone, glucagon-like peptide 1 (GLP-1), increases 
glucose-stimulated insulin secretion and glucose-suppression of glucagon secretion. Insulin stimulates 
blood glucose removal by reducing endogenous glucose production (EGP), stimulating peripheral 
glucose uptake and stimulating glycogen production (B). Modified from Nolan et al. 2011. 
 
1.4.2 From a healthy to a diabetic state 
Type 2 diabetes is characterized primarily by abnormally high levels of glucose in the 
blood as a consequence of insulin resistance and relatively impaired ß-cells function. 
As a compensatory mechanism to the reduced insulin sensitivity, more insulin is 
released from pancreatic ß-cells. Reduced insulin sensitivity in insulin-responsive 
tissues may develop as a consequence of obesity, physical inactivity, and genetic 
predisposition due to an increase in islet ß-cells function (Weir & Bonner-Weir 2004). 
In a pre-diabetes state robust islet ß-cells are able to successfully compensate insulin 
secretion as required, and limit increase in liver fat. In this way, blood nutrient level 
are maintained within the normal range and other tissues, such as the liver, skeletal 
muscle, heart, and ovaries, are not damaged (Nolan et al. 2011). This first stage of 
evolving ß-cells dysfunction during progression to diabetes can last for years (Weir & 
Bonner-Weir 2004). The duration of this pre-diabetes state may vary between different 
ethnic groups. It seems that Caucasian and their descendants differ from other ethnic 
groups because they can withstand more obesity, particularly increased waist 
  
 27 
circumference, before they develop T2D. The WHO therefore recommends to set the 
body mass index (BMI) limit for overweight to 23 kg/m2 and obesity to 25 kg/m2 in 
Asians. Most likely many non-Western populations develop T2D at a lower BMI, 
because of genetic factors in combination with rapid lifestyle changes (Barba et al. 
2004). 
The following steps towards developing T2D are crucial. The islet ß-cells are unable 
to compensate the necessary amount of insulin to maintain a normal glucose level. The 
high blood glucose levels are caused by increased glucagon secretion and reduced 
incretin response, increased endogenous glucose production, increased release of free 
fatty acids from the adipose tissue and development of peripheral insulin resistance 
(Weir & Bonner-Weir 2004; Nolan et al. 2011). In patients with T2D non-oxidative 
glycolysis is enhanced, and lactate production is consequently increased (Del Prato et 
al. 1993).  
Development of T2D is often slow with no clear symptoms early in the disease-phase. 
The diagnosis is therefore often set too late, and it may be complications already at 
time of diagnosis (The Norwegian Directorate of Health 2011). Studies suggest that up 
to 25% of Norwegian individuals with acute myocardial infarction have an 
undiagnosed diabetes (The Norwegian Directorate of Health 2009). Most people who 
get T2D will for several years undergo a stage with impaired glucose tolerance before 
they develop diabetes (Weir & Bonner-Weir 2004). Detection of diabetes and early 
intervention to reverse hyperglycaemia and other cardiovascular risk factors therefore 
is important. Both animal and human studies indicate a cardiovascular and T2D 
preventive effect of lean-seafood consumption.  
 
1.5 The human metabolome 
Metabolomics is the study of the complete collection of metabolites present in cells, 
tissues or biofluids under a particular set of conditions, generating a biochemical profile 
(Nicholson & Lindon 2008). To characterize and quantify molecules in a biological 
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sample, methods such as nuclear magnetic resonance (NMR) spectroscopy and mass 
spectrometry (MS) are often used. MS studies usually require the metabolites to be 
separated before detection, typically by using liquid chromatography (LC-MS). NMR 
is generally used to detect hydrogen atoms in metabolites. All hydrogen-containing 
molecules in a sample will give an NMR spectrum. A typical biological-fluid sample, 
such as human urine, will contain signals from hundreds of metabolites as long as they 
are present in concentrations above the detection limit (Figure 1.3 A). Each metabolite 
will be identified by combining spectra analysis and database queries and by 
comparing, when available, at least two different parameters of the metabolite with 
those of a reference compound (Sumner et al. 2007). Different diets, diseases and 
environment might give different spectra which are possible to separate by this method. 
The intensities of peaks in a spectrum are used as coordinates in multidimensional plots 
of metabolic activity. Each metabolite can be reduced to two- or three-dimensional 
graphs (Figure 1.3 B). Clustering of points can help to visualize and characterize the 
data (Nicholson & Lindon 2008).  
 
Figure 1.3 Raw individual data (1 sample) from an NMR spectrum of a biological fluid with signal of 
metabolites (A) will be identified before pattern recognition techniques reduce multivariate data to a 
two-dimensional plot. This example shows a spectra of biological fluids from 20 samples; nine control 
subjects (green points) and data from eleven disease subjects (purple points) (B). Adapted from 
Nicholson & Lindon, 2008.  
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Targeted approaches focus on a specific subset of the metabolome and provide data 
only on a predefined set of molecules, while untargeted approaches allow for the 
discovery of new molecules and generate new hypothesis (Suhre 2014). Untargeted 
metabolite profiling is used in nutritional studies for a comprehensive analysis of 
exogenous and endogenous low molecular weight metabolites in a biological fluid after 
a dietary intervention (Bertram et al. 2007; Pellis et al. 2012). 
 
1.5.1 Metabolomics as a tool for discovery of metabolic health 
Metabolomics have previously been used to identify early markers of cardiovascular 
diseases and insulin resistance and type 2 diabetes (Roberts et al. 2014; Suhre 2014; 
Soininen et al. 2015) 
The chemical composition of urine is of particular interest, because it reveals key 
information not only about a person's health, but also about what they have eaten. Food 
intake may be reflected by the composition of the urine through two different routes. 
Firstly, food components that are absorbed in the intestine, but not metabolized, 
catabolized or modified in the body will be detected directly in the urine. The detection 
of such urinary metabolites may often directly reflect the composition of the diet. 
Secondly, specific food components may affect specific biochemical processes and 
modify the metabolic state of an organism. Such diet-induced cellular metabolic 
alterations are also reflected in the urine and provide information about how diet 
impacts the metabolic status of the subject. 
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1.6 Aims 
The overall aim of this thesis was to elucidate how lean-seafood can modulate fasting 
and postprandial metabolism of lipid and glucose in healthy humans. 
 
1.6.1 Specific aims in the papers 
The primary outcome of the study was to elucidate the potential of lean-seafood to 
regulate fasting and postprandial plasma lipids and lipoproteins, in order to promote 
cardiovascular health (paper I).  
A secondary outcome of the study was to elucidate the potential of lean-seafood to 
regulate plasma glucose metabolism, in order to prevent development of type 2 diabetes 
(paper II). 
Another predefined outcome was to profile the urinary metabolic response by NMR 
spectroscopy and LC-MS analyses in order to improve understanding of the diet-
induced changes in healthy subjects (paper III).  
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2. Subjects and methods 
 
2.1 Experimental design  
The study was performed in accordance with the ethical standards of the regional 
committee on human experimentation. The Regional Committee for Medical and 
Health Research Ethics of Western Norway approved the protocol, informed consent 
and advertisements (Reference # 2012/1084).  
 
The study design was a randomized crossover design with two experimental periods. 
Cross-over design allocate each participant to a sequence of interventions. Each 
participant received either intervention A or B in the first period and the opposite in the 
succeeding period. The order in which A and B were given to each participant was 
randomized. Approximately half of the participant received the intervention in the 
sequence AB and the other half in the sequence BA. This is so that residual effect from 
first period to second period can be eliminated in the estimate of group differences in 
response. Cross-over designs have a number of possible advantages over parallel group 
trials. Every participant receives every intervention, which in this study means that the 
participant received both a lean-seafood and a nonseafood diet. Therefore, the design 
allows each participant to serve as his/her own control, eliminating among-participant 
variation (Senn 2002). At the end of the first experimental period the participants return 
to their usual dietary habits. A period between interventions is known as a washout 
period as a means of reducing carryover. We had a five-week washout period because 
of Easter time in-between the two periods. Prior to each experimental period, the 
subjects followed a diet in accordance with the Norwegian dietary recommendations 
for 3 weeks (run-in period), with additional specifications to include a maximum of 
one fatty fish (salmon, trout, mackerel or herring) meal per week. The last week of the 
run-in periods and throughout the experimental periods the subjects were instructed to 
avoid alcohol, chocolate or candy, industrial baked cakes or cookies, fast food, 
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probiotics, and fish or fish oil supplements. The subjects were instructed to maintain 
their normal physical activity level during the run-in-, experimental- and washout-
periods. Body weight (kg) was monitored every day for the first week, and every 
second day for the three last weeks in each experimental period. We aimed to maintain 
a stable body weight (± 2 kg) in each experimental period.  
At the first and last day of each experimental period, the subjects ingested a defined 
test meal with fasting and postprandial blood sampling. Morning spot urine was 
collected. At the test day, the subjects were resting and were allowed to drink water 
only, during the 6 hours after ingestion of the test meal. The cross-over study design 
for this study is shown in Figure 2.1. 
 
Figure 2.1 The cross-over study design.  
 
2.2 Study participants 
Healthy Caucasian study participants were recruited from the great area of Bergen 
through web page and newspaper advertisements (Appendix I) during October and 
November 2012. The PhD candidate conducted telephone-interviews with those who 
were interested (n = 148) by using a detailed screening questionnaire (Appendix II). 
The exclusion criteria were: not available in both study periods, use of tobacco; 
diabetes; use of medication known to affect glucose and lipid metabolisms, including 
hormone-based contraceptives; significant alternation in body mass (± 10 %) within 
the last six months; chronic, metabolic or acute disease or major surgery within the last 
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three months; hysterectomy, cholecystectomy, abnormal bleeding during the last 6 
months, and dietary incompatibility with calcium supplementation and/or seafood 
consumption (allergy, intolerance, dislike). The inclusion criteria were healthy 
Caucasian aged between 18 and 65 years old. Those who met the inclusion criteria 
were invited to a pre-study visit (n = 41), were a consultation with physician were 
conducted and fasting blood samples were collected.  
Also, each subject completed a medical and food history questionnaire (Appendix III) 
and a validated food frequency questionnaire (FFQ) (Andersen et al. 2003) (Appendix 
IV). Written informed consent was obtained from all the subjects after they had 
received oral and written information about the study. Based on consultations with a 
physician, 6 subjects were not meeting the inclusion criteria, and additional 5 subjects 
declined to participate. Thirty healthy subjects were invited to participate in the study, 
27 subjects accepted to start. Half of the group (6 men and 8 women) was randomly 
assigned to begin with the lean-seafood diet and the other group (4 men and 9 women) 
to the nonseafood diet. During the first experimental period 6 subjects withdrew; 5 for 
personal reasons and 1 because of an accident. One subject withdrew after period one 
for personal reason. Twenty subjects completed period one (7 men and 13 women) and 
19 subjects (7 men and 12 women) completed the total study (Figure 2.2). Average 
age was for the men 49.7 ± 7.0 (n = 7), for the women 51.0 ± 3.9 (n = 13) and for all 
50.6 ± 3.4 (n = 20). The numbers of subjects that received the lean-seafood and the 
nonseafood diets in period 1 and 2 are outlined in Figure 2.1.  
The participant`s physical and clinical characteristics from the pre-study visit are 
shown in Table 2.1. 
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Table 2.1 The subjects’ physical and clinical characteristics1. 
 Men Women All 
N n=7 n=13 n=20 
Age (years) 49.7 ± 7.0 51.0 ± 3.9 50.6 ± 3.4 
Anthropometric measurements    
Body mass (kg) 86.2 ± 3.2 70.0 ± 2.2 75.7 ± 2.5 
BMI (kg/m2) 26.4 ± 1.1 25.2 ± 0.9 25.6 ± 0.7 
Waist circumference (cm) 95.2 ± 4.2 83.3 ± 2.3 87.5 ± 2.4 
Hip circumference (cm) 98.9 ± 2.0 101.7 ± 1.2 100.8 ± 1.1 
Blood pressure and heart rates    
Systolic blood pressure (mmHg) 130.7 ± 3.5 125.5 ± 2.6 127.3 ± 2.1 
Diastolic blood pressure (mmHg) 78.6 ± 3.2 75.6 ± 2.7 76.6 ± 2.1 
Heart rate (number/min) 63 ± 3 65 ± 1 64 ± 1 
Lipid parameters    
Total cholesterol (mmol/L) 5.0 ± 0.4 5.5 ± 0.3 5.3 ± 0.2 
LDL -cholesterol (mmol/L) 3.5 ± 0.3 3.6 ± 0.3 3.6 ± 0.2 
HDL –cholesterol (mmol/L) 1.3 ± 0.1 1.9 ± 0.1 1.7 ± 0.1 
Total triacylglycerol (mmol/L) 1.1 ± 0.2 0.9 ± 0.1 1.0 ± 0.1 
Glucose metabolism    
Glucose (mmol/l) 5.3 ± 0.2 5.1 ± 0.1 5.1 ± 0.1 
Insulin (pmol/L) 49 ± 11 35 ± 3 41 ± 4 
HbA1C (%) 5.5 ± 0.1 5.4 ± 0.1 5.4 ± 0.1 
Kidney function    
Creatinine (umol/L) 79 ± 3 67 ± 2 71 ± 2 
Liver function    
Alanine aminotransferase (U/L) 36.0 ± 6.2 22.6 ± 1.2 27.3 ± 2.6 
Albumin (g/L) 47.6 ± 1.2 46.9 ± 0.7 47.1 ± 0.6 
Gamma-glutamyltransferase (U/L)  36 ± 9 18 ± 4 25 ± 4 
Total bilirubin (umol/L) 8.4 ± 0.6 7.9 ± 0.8 8.1 ± 0.6 
Alkaline phosphatase (U/L) 63 ± 2 65 ± 4 65 ± 3 
C-reactive protein (mg/L)  2.8 ± 0.4 1.5 ± 0.2 2.3 ± 0.2 
Hematology    
Iron (umol/L) 16.3 ± 1.5 16.4 ± 1.0 16.3 ± 0.8 
Ferritin (ug/L) 155 ± 38 110 ± 23 126 ± 20 
Hemoglobin (g/dl) 15.0 ± 0.3 14.3 ± 0.3  14.6 ± 0.2 
Erytrocytes (1012/L) 4.9 ± 0.1 4.6 ± 0.1 4.7 ± 0.1 
Hematocrit (%) 44.6 ± 1.2  42.5 ± 0.7 43.2 ± 0.7 
Leukocytes (109/L) 5.8 ± 0.6 5.2 ± 0.4 5.4 ± 0.3 
Thrombocytes (109/L) 218 ± 15 270 ± 13 252 ± 11 
Thyroid function    
TSH (mlU/L) 3.0 ± 0.7  2.2 ± 0.3 2.5 ± 0.3 
1 All values are means ± SEM 
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Figure 2.2 Consolidated flow chart for recruitment, randomization and data sampling from the 
participants of the study. 
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2.3 Dietary assessment 
At the pre-visit day all study participants answered a FFQ and a medical and food 
history questionnaire. The medical and food history questionnaire (Appendix III) was 
designed to capture the excluding criteria like change in body mass the last 6 month, 
allergies, food intolerances, use of tobacco, drugs, alcohol, prescriptive medications, 
dietary supplements and/or hormone-based contraceptives and also questions about 
their usual average frequency of fish consumption. Questions regarding seafood intake 
included two summary questions concerning consumption of seafood as dinner and as 
spread. Some of the questions in the medical and food history questionnaire were 
repeated from the oral screening questionnaire by phone (Appendix II). The optical 
mark readable FFQ (Appendix IV) have been developed and validated at the Institute 
of Basic Medical Sciences, Department of Nutrition, at the University of Oslo (UoO) 
and are designed to capture the habitual food intake among adults (Andersen et al. 
2003). The questionnaire contained approximately 180 food items, the options on the 
frequency of consumption of particular food types varied from several times a day to 
once a month, with portion-size choices based on typical household units: slices, 
glasses, cups, pieces, spoons and ladle. Questions about the use of dietary supplements, 
such as cod liver oil, fish oil capsules and some vitamins/minerals were included in the 
FFQ. Intake of nutrients and energy was calculated using a food database in the 
software systems (KBS - `kostberegningssystem`) at the UoO. Since under- and over 
reporting is a prevalent error in dietary self-reports (Kroke et al. 1999; Subar et al. 
2003; Scagliusi et al. 2008), the energy intakes estimated from the FFQ was compared 
with calculated (Harris and Benedict equations) and recommended (Nordic reference) 
energy intakes before the energy level for each subject was chosen (Table 2.2).  
The Harris and Benedict equations provide a method of calculating the energy a person 
expends at rest based on inputs such as their height, age and weight. This value can 
then be multiplied by a correction factor based on the person’s activity level creating 
an estimate for actual energy expenditure (Harris & Benedict 1918). Also the Nordic 
energy requirement references are based on body weight, height, age and either a low, 
average or high physical activity level (The Nordic Council of Ministers 2004). The 
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subjects began the study at the energy level closest to their habitual intake, as chosen 
from comparing the results from International Harris-Benedict equation, the Nordic 
energy requirement references and the self-reportet FFQ (Tabel 2.2). Based on the 
subjects habitual intake six energy levels were established for this study: 7500, 8300, 
9600, 10900, 12200 and 13500 kJ/day.  
 
Table 2.2 Weight, height, BMI, physical activity level, the international Harris-Benedict equation, the 
Nordic energy requirement references, the self-reported FFQ and the level of chosen kJ in the study 
for each subject.  
 
ID Weight 
kg 
Height 
cm 
BMI 
kg/m2 
Exercise 
level 
Harris-
Benedict 
kJ calculated 
Nordic 
reference 
kJ requirement 
FFQ 
kJ self-
reported 
Level of 
kJ chosen 
1 72.6 164.0 27.0 1.7 11086.41 10700 14129 10900 
2 52.0 169.0 18.2 1.5 8460.54 8300 7443 8300 
3 65.1 169.5 22.7 1.5 8659.83 8100 9164 8300 
4 69.8 170.5 23.2 1.6 9461.88 9200 13390 8300 
5 64.5 173.0 21.6 1.5 8584.36 8100 9712 8300 
6 76.9 165.0 28.2 1.6 9613.40 9200 9813 9600 
7 71.4 166.5 25.8 1.5 8668.19 8100 10038 8300 
8 75.8 172.0 25.6 1.6 9603.52 9200 4120 8300 
9 74.1 169.0 25.9 1.5 8846.32 8100 16260 8300 
10 65.6 163.0 24.7 1.5 8127.67 7400 7930 7500 
11 72.4 162.0 27.6 1.5 8502.86 7400 9566 7500 
12 65.5 165.0 23.3 1.6 8588.85 8500 9193 7500 
13 84.0 162.0 29.4 1.5 9067.35 7400 9505 9600 
14 77.0 185.0 22.5 1.6 12604.56 12300 10648 12200 
15 92.7 188.0 26.2 1.5 13084.67 10700 13469 13500 
16 83.4 182.0 25.2 1.7 13079.88 13300 25915 13500 
17 99.3 180.0 30.6 1.5 12116.01 9300 12226 12200 
18 85.3 182.0 25.8 1.6 10999.13 10600 11807 10900 
19 90.2 174.5 29.6 1.5 11113.97 9300 7949 10900 
20 74.0 175.0 24.2 1.6 12022.18 10600 21059 13500 
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2.4 Developing diets 
2.4.1 The experimental diets 
The experimental diets were given as 7-day rotating menus and were formulated to 
meet the Norwegian nutrition recommendations, rich in dietary fiber, vegetables, 
unsaturated fatty acids and limited in added sugar and salt (The Norwegian Directorate 
of Health 2011). We designed two balanced diets that varied in the main protein 
sources. The lean-seafood diet consisted of lunch- and dinner meals with cod, pollack, 
saithe and scallops and the nonseafood diet contained skinless chicken filets, lean beef, 
skinless turkey filets, pork, egg and small amounts of dairy products.  
To calculate the diets we started with the middle energy level, 10900 kJ. The energy 
distribution from the macronutrients were 19 % protein, 29 % fat and 52 % 
carbohydrates of the total energy. The energy content from protein, fat and 
carbohydrates in mixed diet were calculated using respectively conversion factor 16.7, 
37.4 and 16.7 kJ per gram (The Nordic Council of Ministers 2004). Nineteen % protein 
of the total energy level 10900 kJ per day are 2071 kJ protein per day, divided with 
conversion factor 16.7 kJ per gram, gave 124.0 gram protein per day. The protein 
contribution from the experimental protein sources in both diets corresponded to 60 % 
of total protein intake (74.4 gram), and the remaining dietary proteins came from 
vegetable and cereal sources (49.6 gram). The composition of the experimental diets 
were calculated using the Norwegian Nutrition File database (Norwegian Food Safety 
Authority, Mat på data, version 5.1, 2009 linked to Norwegian Food Database 2006). 
A detailed example of a one-day menu from the lean-seafood intervention at the energy 
level of 10900 kJ/day is shown in Table 2.3 and all the other menus from both lean-
seafood and nonseafood are given in Appendix V. All food were precisely measured 
and weighed to the nearest 0.1 g (Figure 2.3). The subjects consumed their breakfasts, 
evening meal and snacks at home, dinners were prepared and served at the University 
College of Bergen, and prepared lunches were provided for the day after. Weekend 
lunches and dinners were distributed on Fridays. The subjects were instructed not to 
consume any food besides the experimental diets.  
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The experimental diets were balanced with equivalent amounts of dietary fiber, 
carbohydrates, protein, lipids, monounsaturated (MUFA), polyunsaturated (PUFA), 
saturated fatty acids (SFA) and content of marine n-3 fatty acids. To balance for the 
marine n-3 fatty acids, 7-day lean-seafood and nonseafood menus including breakfasts, 
lunches, dinners, evening meal and snacks were homogenized, freeze dried, powdered 
and the fatty acid composition were analysed. To balance for endogenous marine n-3 
fatty acids present in the lean-seafood diets, cod liver oil (Möller`s Cod Liver Oil) was 
added (blinded to the participants) to all dinners of the nonseafood diets prior to 
serving. On average, 3.3 gram cod liver oil was added in all dinners at the 10900 kJ 
nonseafood diet. After balancing, the mean EPA+ DHA was 0.82 g per day in both 
diets. The vitamin D level of the lean-seafood diet was lower than the Nordic 
recommendations (The Nordic Council of Ministers 2004), and daily vitamin D3 (10 
μg or 400 IU) supplement was therefore given to the subjects during the lean-seafood 
intervention. Participants did not drink milk during any of the intervention, and only 
small amounts of dairy products were included in the nonseafood diet. Therefore, the 
subjects were given daily calcium supplement; 750 mg during the lean-seafood 
intervention and 500 mg during the nonseafood intervention to meet the Nordic 
recommendations for calcium intake. The nutrient composition of the 7-day menus for 
the 10900 kJ/day lean-seafood and nonseafood diets are outlined in Table 2.4. 
 
 
Figure 2.3 All food were precisely measured and weighed on scale Metos MII-600 (A). Prepared 
Saturday lunches containing cod in sweet & soursauce with broccoli and rice (B). Photos: NIFES 
A 
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2.4.2 The test meals 
At day 0 and day 28 identical test meals were served to the subjects. The test meal 
consisted of cod fillet or lean beef, served with pasta, sauce, vegetables and a cinnamon 
bun, and differed only in the source of experimental protein (Table 2.5). Men were 
given a test meal of 3000kJ and women a test meal of 2250kJ, both consisting of 20% 
energy from proteins, 28% energy from fat and 52% energy from carbohydrates.  
Table 2.5 Ingredients in the test meal with cod and beef as protein source for men, 3000 kJ. 
Test meal with cod Test meal with beef 
87 g Cod 75 g beef 
30 g Cauliflower 30 g Cauliflower 
124 g Potatoes 124 g Potatoes 
14 g Butter 12 g Butter 
4 g Rapeseed oil 2 g Rapeseed oil 
95 g Canned tomatoes 95 g Canned tomatoes 
22 g Onion 22 g Onion 
60 g Carrot 
40 g Broccoli 
60 g Carrot 
40 g Broccoli 
100 g Pasta, whole grain 
50 g Cinnamon bun 
100 g Pasta, whole grain 
50 g Cinnamon bun 
0.9 g Cod liver oil 
 
 
2.5 Sample collection and analyses 
A detailed description of the sample collection and analyses are given in the papers.  
2.5.1 Blood sampling and analyses  
In brief, at the first and last day of each experimental period blood samples were drawn 
from the antecubital vein after an overnight fast. After the subjects had ingested the test 
meal (15 minutes) postprandial blood samples were taken after 0, 30, 60, 120, 240 and 
360 minutes. Serum (after 30 min clotting) and EDTA plasma were separated by 
centrifugation at 2500 g for 5 min at 4 °C and aliquoted to pre-marked tubes. All blood 
samples were thereafter frozen at – 80 °C, except for the plasma used for chylomicrons 
separation that were ultra-centrifuged before stored at – 80 degree freezer (Figure 2.4).  
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Figure 2.4 Overview of blood sampling. Each blood sample was divided into two vacutainers in 
prioritized order, serum and EDTA plasma. Serum was allowed to cloth in room-temperature for 30 
minute before being centrifuged, while plasma was immediately split into two containers and thereafter 
centrifuged separately. Serum and plasma was aliquoted into dedicated tubes in prioritized order, and 
stored at -80 degree freezer until transported to different laboratory. HUH = Haukeland University 
Hospital, Department of Laboratory Medicine and Pathology. 
 
Serum and plasma samples were analysed for standard clinical chemistry parameters 
and hormones involved in the regulation of lipid- and glucose metabolism. Overview 
of analyses on serum and plasma, and at which laboratory they were performed are 
outlined in Table 2.6. 
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Table 2.6 Analyses performed on fasting and postprandial blood samples. 
Analyses Matrix Laboratory   
Lipid metabolism    
   TAG s HUH  
   Cholesterol, total s  HUH  
   HDL-cholesterol s  HUH  
   LDL-cholesterol s HUH  
   Apolipoprotein B s  HUH  
   Apolipoprotein A1 s HUH  
   TAG in CM-fraction ep HUH  
   TAG in non-CM fraction ep  HUH  
   Lipoproteins by NMR ep LipoScience1  
Glucose metabolism    
   Glucose s HUH  
   Total bile acids s HUH  
   NEFA s NIFES  
   OH-butyrate s NIFES  
   Lactate s NIFES  
   Glycerol s NIFES  
   Urea s NIFES  
   Insulin s HUH  
   C-peptide s HUH  
   Glucagon ep HUH  
   Adiponectine s NIFES  
   Ferritin s HUH   
   Transferrin reseptor s HUH  
   C-reactive protein s HUH   
Metabolomics    
   Metabolomics by NMR s University of Aarhus  
1 = LipoScience (Raleigh, NC, USA) 
s = serum 
ep = EDTA plasma 
HUH= Haukeland University Hospital, Department of Laboratory Medicine and Pathology 
 
EDTA plasma was ultra-centrifuged at 41 000 g for 35 min at 4 °C at NIFES on the 
blood sampling day. The top and lower fraction were collected and stored at -80 °C 
freezer before analysed for respectively TAG in chylomicrons and TAG in non-
chylomicrons (containing very low-density lipoproteins, chylomicron remnants, low-
density lipoproteins and high-density lipoproteins). A comprehensive lipoprotein 
profile was determined by NMR and particle number of total VLDL (VLDL-P, 
nmol/L), LDL (LDL-P, nmol/L) and HDL (HDL-P, μmol/L), along with large, medium 
and small subclasses and a weighted average particle diameter for each. These analyses 
were bought from LipoScience (Raleigly NC, USA).  
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2.5.2 Urine sampling 
Morning spot urine was collected on day 1 and 28 of each experimental period. The 
urine was aliquoted, frozen at – 80 °C before analysed, using NMR spectroscopy and 
LC-MS platforms. These analyses were performed by a PhD student at University of 
Aarhus. 
2.5.3 Dual-energy x-ray absorptiometry (DXA) 
Dual-energy x-ray absorptiometry (DXA) was used to measure body composition; total 
fat mass, fat % and total lean mass. All scanning procedures were conducted by trained 
medical staff following the same protocol. 
 
2.6 Statistical analyses 
The number of research participants are based on a Canadian study, in which similar 
interventions previously were performed (Ouellet et al. 2007; Ouellet et al. 2008). 
Sample size has been calculated based on the efficacy of lean fish to reduce plasma 
VLDL-TAG (Gascon et al. 1996) and on the procedure described by Wellek and 
Blettner (2012) for crossover design in clinical trials. A minimum of 16 subjects was 
needed to detect a treatment difference of ~25-30% in fasting plasma TAG at a 
probability level inferior to 0.05 and a power level corresponding to 80%. A similar 
calculation has been performed based on postprandial TAG response to dietary protein 
(Mortensen et al. 2009). A minimum of 12 subjects was needed to detect a treatment 
protein effect of ~30% at a probability level inferior to 0.05 and a power level 
corresponding to 80%. Therefore, from those calculations and in order to be 
conservative, we chose the power calculation based on fasting VLDL-TAG.  
We increased our number of subjects to 30 per experiment by taking into account an 
eventual 25% loss of subjects. We therefore invited 30 subjects to participate in the 
study, 27 subjects started, 20 completed period 1 and we obtained postprandial samples 
from 19 (Figure 2.2).  
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Statistical analyses were performed using the Statistical Analysis System (version 9.3; 
SAS Institute, Cary, NC). The PROC MIXED procedure for an ANOVA for crossover 
design with two periods as described by Hills and Armitage (1979) was used to 
compare the effects of the two dietary treatments on anthropometric measurements, 
lipid and glucose parameters. As no effect of experimental period or diet sequence and 
no residual effect of the first experimental period over the second period was observed 
for any of the measured variables, the data for experimental period, diet sequence, and 
dietary treatment were pooled. Standard Bonferroni correction has been performed to 
reduce the chances of obtaining false-positive results. Furthermore, repeated-measures 
analysis of variance were applied for variables with repeated measures over time during 
the test meal. The Least Squares Means Test was performed to compare the changes 
(post to pre) values for each diet. For all measures, P < 0.05 was considered as 
statistically significant. Data are expressed as means ± SEM. 
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3. Summary of results 
3.1 Paper I 
Lean-seafood intake reduces cardiovascular lipid risk factors in healthy subjects  
Objective: The primary aim of this study was to elucidate the potential of two main 
dietary protein sources, lean-seafood or nonseafood, to modulate fasting and 
postprandial lipids in healthy subjects. We hypothesized that lean-seafood intake would 
reduce cardiovascular lipid risk factors in healthy subjects, as compared to intake of 
nonseafood protein sources.   
 
Results:   
x Lean-seafood, as compare to nonseafood intake, reduced fasting (P = 0.03) and 
postprandial (P = 0.01) serum TAG concentrations.  
x Lean-seafood intake reduced postprandial (P = 0.02) medium-sized VLDL 
particle concentrations.  
x Lean-seafood intake prevented elevation in fasted (P = 0.03) and postprandial 
(P = 0.01) total- to HDL cholesterol ratio.  
 
Conclusions: Dietary protein source determines fasting and postprandial lipids in 
healthy subjects in a manner that may have beneficial effect on long-term development 
of cardiovascular disease.  
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3.3 Paper II 
Lean-seafood intake reduces postprandial C-peptide and lactate concentrations 
in healthy subjects 
Objective: Our secondary aim was to elucidate the potential of two main dietary protein 
sources, lean-seafood or nonseafood, to modulate fasting and postprandial glucose 
metabolism in healthy subjects. We hypothesized that lean-seafood intake would affect 
postprandial glucose metabolism differently from nonseafood in healthy subjects.   
 
Results:  
x The dietary intervention did not cause significant changes in fasting and 
postprandial serum insulin and glucose concentrations. 
x Lean-seafood intake reduced postprandial C-peptide (P = 0.04) concentrations.  
x Lean-seafood intake reduced postprandial lactate (P = 0.04) concentrations.  
x Lean-seafood intake reduced fasting (P = 0.002) and postprandial (P = 0.002) 
TAG/ HDL-cholesterol ratio. 
 
Conclusion: Dietary protein source determines postprandial glucose metabolism in 
healthy subjects in a manner that may have impact on long-term development of 
insulin-resistance, type 2 diabetes and cardiovascular disease. 
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3.4 Paper III 
Lean-seafood intake improves mitochondrial oxidative capacity as indicated by 
human urinary metabolomics 
Objective: We hypothesized that intake of different protein sources would alter key 
metabolic pathways, and that these modified effects were reflected in the urine 
metabolome. The profiling was conducted using NMR spectroscopy and LC-MS 
analysis, in order to improve understanding of the effects of dietary changes on 
metabolic status. 
Results:  
x Nonseafood intake increased the urinary level of 3-methylhistidine (3MH) (P = 
0.002). 
x Lean-seafood intake reduced the urinary level of N1-methyl-2/4-pyridone-5/3 
carboxamide (2PY) (P < 0.01). 
x Lean-seafood intake reduced the urinary levels of L-carnitine (P <0.01) and an 
acylcarnitine (P < 0.03). 
x Lean-seafood intake increased the urinary level of trimethylamine N-oxide 
(TMAO) (P < 0.01). 
x The content of TMAO was higher in the lean-seafood diet (P ≤ 0.001). 
 
Conclusion: 
Based on the urinary metabolomics analyses, our data suggest that in healthy subjects 
four weeks of lean-seafood intervention improved mitochondrial oxidative capacity 
that may have facilitated lipid catabolism. In contrast, four weeks on nonseafood 
intervention may have increased protein catabolism.   
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4. Discussion 
 
4.1 Methodological considerations 
4.1.1 The study design 
In a randomized controlled trial (RCT) the subjects are randomly assigned to treatment 
groups. Both groups will be treated identically in all respects except for the intervention 
being tested. RCTs are the most powerful tools in clinical research and are considered 
to be the “gold standard” for generating reliable evidence (Moher et al. 2012). The 
randomization avoids systematic errors, and thus confounding effects are statistically 
less likely to occur (Higgins & Green 2011). The subjects in the present study were 
randomly assigned to start with one of the two dietary interventions. No biochemical 
or anthropometric variables were used for randomization purpose. Randomization was 
done by putting 30 pieces of papers, each piece with one of the participants ID number, 
and in an alternating order assigning the subjects to start with the seafood or nonseafood 
diet by picking the paper pieces sequentially from the box. Randomization does not 
necessarily result in equal groups with respect to age, gender or other characteristics, 
but in a cross-over design each subject is receiving both interventions. Since each 
subject is receiving all treatments, also variability is reduced, because the measured 
effects of the interventions are the difference in an individual subject’s response to the 
intervention, in the present study being lean-seafood and nonseafood interventions. 
This reduction in variability makes it possible to use smaller sample sizes, while 
retaining the ability to detect specific differences in response (Friedman et al. 2010). 
Since dropout is common in clinical trials, this was taken into account in the power 
calculation.  To account for an expected dropout in such an intervention, we recruited 
more subjects than necessary to maintain the statistical power at the end of the study. 
A reduction in variability was also achieved by including only Caucasian subjects, 
leading to a more homogenous group and probably resulting in lower variations of the 
data, and more accurate results (Moher et al. 2012). 
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Ideally, neither the subjects nor the investigator should know who is in which group to 
avoid any influence of pre-conceived ideas among the participants or the investigators. 
In the present study the sequence of dietary intervention was concealed until one week 
before study start. Thereafter, blinding was not feasible due to the nature of the 
intervention. Blinding was re-established during sample analysis and statistical data 
analysis, since un-blinded laboratory and data analysis may introduce bias through the 
choice of analytical approach (Gluud, 2006). In this study the technicians performing 
the analyses were blinded by giving the samples unique number codes.  
There are several challenges related to conduction of crossover studies, e.g. the risk of 
carryover effect and avoiding drop-outs. To avoid that the effect of the intervention 
during the first period must not carry over into the second period a washout period of 
5 weeks was included in the design. Also a 3 week run-in period was completed in 
advance of each intervention period to minimize order effects (Higgins & Green 2011). 
During this period, participants were instructed to avoid certain foods e.g. chocolate or 
candy, industrial baked cakes and fast foods. Another challenge with crossover studies 
is the risk of drop-outs due to their longer duration. Since the study was demanding to 
the subjects and the scientists, it is of importance to minimize the experimental 
duration. We also choose the intervention periods to be 4 weeks, based on previous 
experience shown to be sufficient to obtain diet-induced changes in fasting lipid 
concentrations (Jacques et al. 1992; Gascon et al. 1996; Ouellet et al. 2007). To avoid 
drop-out all lunches and dinners were free and a lot of effort was put into the flavor 
development of the experimental diets. In addition to that the meals should look and 
taste good, the atmosphere in the serving room should be welcoming to the participants 
every day. The participants were given an economic compensation after every test day. 
This compensation was meant to cover travel expenses during the study. Throughout 
the study period we had daily talks with the study participants and were available if 
they had any questions. After completion of the study we arranged a gathering were 
the participants got an individual feedback on some of their results from the study 
(fasting concentrations of TAG, total cholesterol, LDL-C, HDL-C, glucose and insulin) 
and body composition (body weight, lean mass, fat mass, fat %).  
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Half of the study group started with lean-seafood diet, and the other half with the 
nonseafood diet. Use of crossover design has an advantage that fewer participants are 
required, to avoid between-participant variation when estimating the intervention 
effect. The ability to justify the use of crossover as a design still depends on a test for 
carryover that includes between-participant variability (Friedman et al. 2010). The 
present study had no effect of experimental period or diet sequence and no residual 
effect of the first experimental period over the second period for any of the measured 
variables. One exception was the body mass, as the participants lost more body weight 
in the second period compared to the first period. This period effect was not influenced 
by diet, and the weight reduction was equally in both interventions. A possible 
explanation for increased weight loss in the second period may be because the 
participants were more physically active due to the season in the second period (April 
to May). Hills & Armitage (1979) pointed out that also the scientific community should 
be convinced by the substantial evidence that the design has no carryover effect.    
 
4.1.2 The Food Frequency Questionnaire 
The Food Frequency Questionnaire is the most common dietary assessment method 
used in large epidemiologic studies of diet and health. The self-administered FFQ asked 
the subjects to report the frequency of consumption and portion size of food items over 
a defined period of time (e.g. the last month; the last six months). To answer an FFQ 
relies heavily on the subjects` ability to recall the foods he/she usually eats and to 
conceptualize portion sizes. The FFQ is therefore susceptible to measurement errors, 
as with the use of any dietary assessment instrument (Kipnis et al. 2002). 
The validated FFQ we used had 180 food items included (Andersen et al. 2003) and 
may for some of the participants  have felt burdensome and possibly led to careless 
completion and lower data quality. For that reason, we could have used a shorter FFQ 
that was easier for the participants to complete, if the purpose was only to assess the 
total energy intake (EI). However, important information might be missed and only the 
most commonly consumed foods would have been captured. Whether the participants 
  
 53 
are male or female could impact the FFQ results. Young women are possibly more 
weight conscious than young men, and this could lead to higher underreporting of FFQ. 
In studies from USA (Subar et al. 2003), Brazil (Scagliusi et al. 2008) and Germany 
(Kroke et al. 1999) women showed to underestimate the EI when using an FFQ, as 
compared to diet recalls, diet histories and food records methods. In a Norwegian study 
comparing EI assessed with an FFQ, the underestimation among women was not 
statistically significant (Andersen et al. 2003). Underreporting varied largely from one 
study and country to another, but taken together the evidence points to no general 
difference according to gender (Subar et al. 2003; Scagliusi et al. 2006; Freedman et 
al. 2014). This is in agreement with our finding were 54 % of the women and 57 % of 
the men were either under- or over reporting their EI (Table 2.1). Regardless of gender, 
40 % of the participants were over estimating, and only 15 % of the participants were 
under estimating their EI in the present study. The over and under estimation of intakes 
can result from a time consuming process of answering the FFQ, or that the participants 
answer the questionnaire in the fasting state. Individual factors might, however, make 
the participants to misreport to the same extent regardless of dietary assessment 
method. The FFQ method is anyway inaccurate for assessing the individuals intake, 
therefore we compared the participants self- reported intake with calculated (Harris & 
Benedict 1918) and recommended (The Nordic Council of Ministers 2004) energy 
intake. Thus, the energy intake level of each participant was validated using three 
different dietary assessment methods. 
 
4.1.3 The experimental diets  
The experimental diets were balanced with equivalent amounts of dietary fiber, 
carbohydrates, proteins, lipids, MUFA, PUFA, SFA and content of marine n-3 fatty 
acids. The participants were not eating nutrients but foods, and a challenge in 
developing experimental diets was to prepare appetizing dishes. Food that looks 
unappetizing are often not eaten. Foods that are discolored, in odd shapes, or otherwise 
atypical are usually regarded with suspicion. But less obvious is the fact that visual 
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cues can alter not just the acceptability of foods, but also modify the perception of taste, 
odor and flavor (Delwiche 2004). The literature indicate that increase in color level in 
a dish, also increases taste and/or flavor intensity, while other studies means that the 
effect is resulting from learned associations rather than from inherent psychophysical 
characteristics (Clydesdale 1993).   
The color, smell, taste, temperature, texture and sound interact with each other, and 
they all have an impact on flavor ratings and have a tremendous impact on whether 
foods and drinks will be accepted or rejected, and liked or disliked. Of additional 
importance in developing healthy experimental diets were to use herbs, fresh seafood 
and meat, vegetable with different colors and vegetable with lots of flavor such as 
garlic, onion, parsley root and celeriac. The subjects` acceptance of the diets can be 
attributable to that they really liked it, or that their perception of the diets performance 
benefits, because the diets are “therapeutic” or “healthy” in itself. A “healthy diet” in 
a study will have a different set of expectations by the participants from an “ordinary 
diet” (Civille & Oftedal 2012). 
Development of enriched food products is commonly used in industry, and often are 
the ingredient being enriched imparting a distinct flavor or texture. To balance for the 
endogenous marine n-3 fatty acids present in the lean-seafood diet, we added cod liver 
oil to all of the nonseafood dinners. During dietary intervention study like this, high 
compliance is crucial, and so reduction of off-flavors or bitter tastes becomes 
increasingly important. Masking the cod-liver oil is challenging, as the ingredient has 
distinctive visual characteristics and a particularly strong flavor and aftertaste. Through 
pilot testing among the kitchen personel, we found that dinner sauces in the nonseafood 
diet was the best delivery method to mask the cod-liver oil flavor. Since some of the 
subjects in the pilot testing, felt the cod-liver oil flavor because they knew it was added, 
we decided to blind the cod-liver oil for the participants in the study.   
The nutritional composition of the experimental diets were equal, they only varied in 
the main protein sources. In addition we aimed to make the two diets look as similar as 
possible, similar in physical characteristics (gross morphology, appearance, volume 
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and texture) and sensory qualities (mouthfeel, taste, palatability and breakdown 
characteristics in the mouth). We managed this to a large extent by using the same side 
dishes, vegetable or the same ingredients in the sauce. Since different preparation and 
cooking method may have an impact on the results (Patel et al. 2012) we prepared the 
meals in the same convection oven, except for the red meat that was fried in a dry pan 
without frying media.  
Another aspect to consider is site or location where the meals are served, the 
atmosphere, the temperature in the room, table, chairs, use of napkins, lighting and so 
on do all have an impact of the appealing to the servings (Nyberg & Grindland 2008). 
In our study we aimed to standardized these conditions.  
 
4.2 General discussion 
The main results of this thesis is that intake of lean-seafood positively influenced the 
risk factors for CVD and T2D. Prevention of CVD and T2D is a public health goal and 
comprises several avenues of action. Achieving a healthy lifestyle true particular 
increased physical activity, dietary patterns and nutrient intake can play a role in CVD 
and T2D prevention.  
Healthy subjects had after 4 weeks lean-seafood intervention, a significant reduction 
in fasting and postprandial circulating TAG concentrations adjusted according to 
Bonferroni correction, relative to the 4 weeks nonseafood intervention (Paper I). There 
is evidence that raised circulating TAG levels are associated with increased coronary 
heart disease risk, adjusted for established coronary risk factors (Nordestgaard et al. 
2007). In the same meta-analyses, using data from more than 300 000 participants in 
prospective studies, the hazard ratio for coronary heart disease, adjusted for age and 
sex only, was 1.10 per 16% higher TAG concentration (Sarwar et al. 2010). In our 
study, we observed that lean-seafood intervention reduced the fasting concentration of 
TAG with 16%, whereas intervention with nonseafood increased the fasting 
concentration of TAG with 13%. The postprandial TAG concentration was also lower 
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after the lean-seafood intervention, and the average difference in postprandial TAG 
concentration over the 6h time-course was about 0.3 mmol/L after ingestion of cod and 
beef test meals. A meta-regression analysis of pharmacological lowering of TAG with 
fibrates indicated that a 0.1 mmol/L decrease in triglycerides caused a 5 % reduction 
in coronary events (Jun et al. 2010). Based on the estimates from the Emerging Risk 
Factors Collaboration (Sarwar et al. 2010), the lean-seafood intervention in our study 
reduced the coronary heart disease hazard ratio by close to 20% relative to the 
nonseafood intervention. Our finding with dietary protein from lean-seafood, 
compared to protein from nonseafood, reduced circulating TAG concentration in 
healthy subjects at a magnitude that might be preventive against future CVD.  
The present study showed a lipid-lowering effect after consumption of lean-seafood. 
Seafood is a rich source of taurine (2-aminoethanesulfonic acid) whereas terrestrial 
animal proteins generally are lower in taurine, and milk proteins and vegetable proteins 
are virtually deficient in taurine (Spitze et al. 2003). This corresponds to the higher 
level of taurine in the experimental diet with lean-seafood (0.3 weight% of total amino 
acids), compared to the experimental diet with nonseafood (0.1 weight% of total amino 
acids) (Paper I). Taurine supplementation has been reported to reduce blood TAG in 
overweight and obese non-diabetic humans (Zhang et al. 2004). Fish consumption 
significantly results in inverse relationship between urinary taurine excretion and 
coronary heart disease mortalities (WHO-CARDIAC Study) (Yamori et al. 2004). 
Taurine may be an important amino acid in fish to explain the beneficial effects of fish 
on the prevention of CVD. Other amino acids could also play a role. Conclusion based 
on the high level of taurine in the lean-seafood diet alone should not be drawn, but 
taurine is a conditionally essential nutrient.  
The amount of total cholesterol concentration decreased significantly after both lean-
seafood and nonseafood diets intervention. Also the LDL cholesterol concentration 
decreased by both interventions (Paper I). The reduced concentration of total 
cholesterol and LDL cholesterol may be explained by the healthy diet high in dietary 
fiber and the complete absence of alcohol, chocolate or other sweets. The healthy diets, 
in combination with the reduced body weight during the interventions, may have 
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contributed to the reduced total cholesterol and LDL cholesterol concentrations. Both 
diets also reduced concentration of the independent CVD risk factor HDL-cholesterol 
(Rader & Hovingh 2014) but the lean-seafood intervention attenuated this decrement. 
Thus the change in the strong cardiovascular risk predictor circulating total- to HDL-
cholesterol ratio, was significant lower after the lean-seafood intervention (Paper I). 
The subjects had no change in apolipoprotein A1 or total HDL particle concentrations, 
suggesting that after the lean-seafood intervention the HDL particles contained more 
cholesterol per HDL-particle than after the nonseafood intervention.  Our results after 
4-week with nonseafood diet are consistent with previous studies, showing that 
increases in circulating TAG concentration are associated with greater reductions in 
HDL cholesterol than in ApoA1 (Tremblay et al. 2007; McQueen et al. 2008). A 
mechanism has been suggested in which core lipids are exchanged between HDL and 
VLDL particles, in combination with elevated hepatic lipase activity, producing 
cholesterol-poor HDL particles or reduced size (Rashid et al. 2003). In our study, the 
nonseafood intervention led to a lower ratio of HDL- to total cholesterol, and higher 
concentration of medium-sized VLDL particles, resembling the altered lipoprotein 
interaction previously suggested to take place during development of dyslipidemia 
(Rashid et al. 2003; Tremblay et al. 2007; McQueen et al. 2008). Our results suggest 
that 4 weeks of lean-seafood intervention protected healthy subjects from developing 
a metabolic dyslipidemia pattern with elevated postprandial concentrations of TAG and 
VLDL particles, and an elevated total-to-HDL- cholesterol ratio.  
The lipoprotein profile obtained after lean-seafood intervention is contradictory to the 
diabetic dyslipidemia frequently preceding development of type 2 diabetes (Adiels et 
al. 2008), suggesting that insulin signaling could be involved in the diet-induced 
alterations of lipoprotein profiles observed in the present study. 
Since insulin, but not C-peptide, is extracted by the liver, serum C-peptide level reflects 
endogenous insulin secretion more directly than does serum insulin level (Weir & 
Bonner-Weir 2004). In our study postprandial C-peptide concentration decreased after 
the lean-seafood intervention, resulting in a significant (P = 0.04) difference between 
the two diet interventions (Paper II). This indicated different insulin release from 
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pancreatic ß-cells. The increased insulin secretion after consumption of nonseafood, 
may be an indicator for early insulin resistance (Weir & Bonner-Weir 2004; Nolan et 
al. 2011). Despite the reduced postprandial C-peptide concentration after the lean-
seafood intervention, the glucose concentration was maintained. Our results indicated 
improved insulin sensitivity after lean-seafood diet, which was also observed in insulin 
resistant subjects after 4 weeks on a cod-based diet compared with subjects ingesting a 
meat-based diet (Ouellet et al. 2007). Another test meal-study in healthy humans 
showed lowered insulin levels and reduced insulin-to-C-peptide and insulin-to-glucose 
ratios when given a cod protein meal, compared with a milk protein meal (von Post-
Skagegard et al. 2006). These results indicates that insulin works better, or that other 
components amplifies the insulin signal after eating cod or lean-seafood. Our study was 
conducted in healthy subjects, with healthy balanced diets, and still resulted in a 
significant different postprandial C-peptide concentration. This shows that adjustment 
in diet, may have preventive effect on T2D development.  
Lactate is a marker of glucose oxidation (Figure 4.1). In our study postprandial lactate 
concentration decreased after lean-seafood, and increased after the nonseafood 
intervention, despite equal postprandial glucose concentrations in the subjects (Paper 
II). An increased circulating lactate concentration has traditionally been used as an 
indicator of energy imbalance related to vigorous exercise and hypoxia (Sabatine et al. 
2005). However, in our study lactate was not increased as a result of exercise since all 
the participant were resting during the test day. A possible explanation for the increased 
lactate levels could be an inadequate oxidative capacity at the cellular level. Indeed a 
study in subjects with impaired glucose tolerance or insulin sensitivity demonstrated 
increased plasma lactate production during a 75 g oral glucose tolerance test (Berhane 
et al. 2015). In our study we served our subjects a test meal, with carbohydrate levels 
of 64 grams for women and 85 grams men. Juraschek et al. (2013) have also observed 
a strong, graded relationship between plasma lactate and subsequent risk of incident 
type 2 diabetes over a 9-year follow-up period.  
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Figure 4.1 Lactate in glycolysis in healthy and type 2 diabetic subjects. Insulin stimulate glucose 
uptake into the insulin-responsive tissues. In healthy subjects ~1/3 of glucose is stored as glycogen, 
and rest goes true glycolysis where most is oxidized (A). The ability to synthesize and store glycogen 
after meal is impaired in subjects with impaired insulin-sensitivity and type 2 diabetes, and more of 
the glucose enters glycolysis. The oxidative capacity decreases, and plasma lactate concentration 
increases as a consequence of greater flux through glycolytic pathways (B). 
Lactate metabolism is profoundly related to glucose metabolism. After meal ingestion, 
the blood glucose and insulin transiently increase. The increased level of circulating 
insulin stimulate uptake of glucose and storage to glycogen. Glucose is producing 
pyruvate true glycolysis. Pyruvate is either being converted to acetyl CoA that can enter 
the Krebs cycle or being converted to lactate leading to higher circulating lactate 
concentration (Figure 4.1). The relative increase in postprandial lactate concentration 
after the nonseafood intervention in the present study might indicate impaired insulin 
sensitivity (Juraschek et al. 2013; Berhane et al. 2015). Whether decreased oxidative 
capacity itself is a cause or consequence of insulin resistance and diabetes is unknown. 
Another potential explanation for the relationship between lactate and incident diabetes 
is expression and activity of GLUT4, the glucose transporter in muscle and fat cells. In 
response to insulin, GLUT4 sequesters glucose into muscle and fat cells where it might 
undergo glycolysis. There is evidence that elevation of plasma lactate suppressed 
glycolysis before its effect on insulin-stimulated glucose uptake, consistent with the 
hypothesis that suppression of glucose metabolism could precede and cause insulin 
resistance. Lactate-induced insulin resistance was associated with impaired insulin 
signaling and decreased insulin-stimulated glucose transport in skeletal muscle (Choi 
et al. 2002). From a study with rats fed a high-fat diet, the cod protein feeding, 
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compared to soy protein and casein feeding, prevented rats from developing skeletal 
muscle insulin-resistance (Lavigne et al. 2001). Our finding that lean-seafood, relative 
to nonseafood intervention reduced postprandial lactate, is another indication that lean-
seafood intake may preserve normal glucose metabolism in healthy subjects.  
Intake of lean-seafood in 4 weeks as the main protein source resulted in significant 
higher level of TMAO in urine. This finding can be explained by the high level of 
endogenously TMAO from marine fish in the lean-seafood diet (Paper III). The content 
of TMAO in marine fish is between 40 – 120 mg/kg, compared to fresh-water fish 
which contain only 0 – 5 mg/kg (Belitz et al. 2009). This corresponds to the significant 
higher level of TMAO in the experimental diet with lean-seafood, compared to the 
experimental diet with nonseafood (Paper III). TMAO may also be derived from 
hepatic oxidation of trimethylamine (TMA), generated by gut flora from dietary 
phosphatidylcholine, choline and carnitine (Tang et al. 2013). Hence, TMAO may end 
in the human urine either from dietary sources, but may also be produced through the 
gut flora. TMAO produced through the gut flora pathway has been associated with the 
development of atherosclerosis (Koeth et al. 2013) and cardiovascular disease (Tang 
& Hazen, 2014). Since especially marine fish is a major source of TMAO, a higher rate 
of CVD among fish-consuming people would be expected. In contrast, a low rate of 
CVD have been reported with regular fish consumption in a large number of 
prospective studies (Dyerberg et al. 1978; Kromhout et al. 1985; Leon et al. 2008; 
Mozaffarian & Wu 2011). The present study showed a relatively clear anti-atherogenic 
lipoprotein profile after consumption of lean-seafood. Conclusion based on the total 
TMAO alone should not be drawn, but TMAO could merely be a biomarker and not a 
causal compound.  
In the present study we observed a significantly increased level of 3MH in urine 
samples collected after nonseafood intervention (Paper III). This is in line with studies 
showing that 3MH is excreted in the urine after meat consumption (Huszar et al. 1983; 
Neuhauser et al. 1984). However, frequent meat-eaters (Spain) had higher urinary 3-
Methylhistidine (3MH) as compared to frequent fish-eaters (Japan) (Horie et al. 1990). 
Our data with increased 3MH from the `meat-eaters` support that urinary level from 
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3MH in fact comes from muscle protein degradation or protein turnover. As insulin 
attenuates protein-catabolism in healthy subjects, protein-catabolism, and thus urinary 
3MH excretion, is increased in insulin resistance subjects (Lattuada et al. 2004). This 
suggests impaired insulin sensitivity after the nonseafood intervention in the present 
study. 
Our metabolomics data showed a significant increased level of an acylcarnitine in the 
urine samples after nonseafood intervention. An increase in plasma acylcarnitines may 
be a biomarker of dysfunctional mitochondrial fatty acid oxidation (Adams et al. 2009), 
and is associated with impaired insulin sensitivity (Mihalik et al. 2010). We observed 
a significantly decreased level of 2PY (a NAD catabolite) in the urine samples collected 
after lean-seafood intervention compared to the nonseafood intervention, possibly 
suggesting a better maintenance of mitochondrial respiration (Paper III). This 
reduction-oxidation complex aiding the electron transport in the mitochondria is 
required to produce energy, which could indicate a regulation or a metabolic switch in 
energy production. Decreased NAD catabolism may protect against mitochondrial 
saturation, suggesting why lean-seafood reveal decreased TAG and VLDL and not an 
increase in urinary acyl carnitines. Our results may suggest improved preservation on 
insulin sensitivity after lean-seafood, while nonseafood intervention may lead to 
impaired insulin sensitivity. 
As discussed, a diet high in lean-seafood is linked to beneficial outcomes. It is evident 
that the prevalence of lifestyle related diseases is increasing. CVD and stroke were the 
top cause of death in the world in 1990, and remains the top in 2010. Noteworthy, CVD 
and stroke increased 26-35% over the interval. The cause-specific death rate seem to 
drive a broad shift from communicable, maternal, neonatal, and nutritional causes 
towards non-communicable diseases (Lozano et al. 2012). According to the 
“Reseptregisteret” more than 170.000 Norwegians were on diabetes medication in 
2014 (Norwegian Institute of Public Health 2015). The increased use oral 
hypoglycaemic agents, of insulin in type 2 diabetes, and the frequent prescription of 
statins and antihypertensive agents may have resulted in further reliance on 
pharmacological rather than nutritional treatment. This thesis has shown that lean-
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seafood intake may reduce risk factors for development of CVD and T2D, ranked 
number 1 and 9,  respectively, on global death causes in 2010 (Lozano et al. 2012). An 
increased intake of lean-seafood should be encouraged as a part of a healthy diet in the 
prevention of CVD and T2D, and therefore have a part of combating these health 
challenges.  
 
4.3 Conclusions 
Based on our data lean-seafood regulates fasting and postprandial lipids and glucose 
metabolism differently in healthy subjects after four weeks.  
x Lean-seafood intake modulates fasting and postprandial lipids in healthy 
individuals in a manner that may have an effect on the long-term development 
of cardiovascular disease.  
x Lean-seafood intakes determines postprandial glucose metabolism in healthy 
subjects in a manner that may have impact on long-term development of insulin-
resistance, type 2 diabetes and cardiovascular disease.  
x Lean-seafood intake, based on the urinary metabolomics in healthy subjects, 
suggests improved mitochondrial oxidative capacity that may have facilitated 
lipid catabolism.  
 
4.4 Future perspectives 
This intervention with two hot dishes per day gave a higher intake of lean-seafood per 
week, compared with the recommended amount. In addition, the intervention was 
different from the common dietary pattern and food culture in Norway, which 
consists of only one hot meal per day. Further studies could be carried out with only 
one hot dinner serving per day, resulting in a lower weekly intake closer to the 
average intake of lean-seafood in Norway. To test if also lower intake for a longer 
period of time would give similar results.  
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In addition to performing the study in a strict-controlled intervention, another trial 
could be conducted in a more realistic setting. A free-living intervention would test 
the real-world setting. The general population might consider free-living studies more 
achievable, due to less demanding condition for the subjects. To retain sufficient 
statistical power, the study sample should be increased to be able to detect differences 
between the dietary intervention groups. 
In this intervention a diet high in lean-seafood resulted in beneficial outcomes in 
healthy subjects. It could also be of interest to evaluate the therapeutic potential of 
lean-seafood. Further studies could be carried out with insulin resistant or diabetic 
type 2 subjects.  
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Appendix II 

 ID: _____________ 
Dato: ___________ 
      Rekruttering per telefon 
 
Etternavn :        Alder :   
Fornavn :        Kjønn : K M 
Telefon :             
   (hjemme)     (arbeid)   (mobil) 
Postadresse: ___________________________________ 
E-post: ___________________________ 
 
Er du av kaukasisk avstamming (hvit hudfarge)?  □ Ja □ Nei □ Vet ikke 
 
Kroppsvekt (kg)    
Høyde (m)     
BMI (kg/m2)     
 
Vil du være tilgjengelig uke 4-8 og uke 16-20, 2013?    □ Ja □ Nei □ Vet ikke 
Vil det være mulig for deg å bruke en hel dag i uke 4, 8, 16 og 20? □ Ja □ Nei □ Vet ikke 
 
 
Kvinner: 
Menopause?  □ Ja  □ Nei 
Hormonbehandling? □ Ja       □ Nei  Dersom ja, hvilke hormoner?   
Hormonprevensjon? □ Ja  □ Nei  Dersom ja, hvilke hormoner?   
 
 
        (Evt. kan du sjekke?) 
Har du: 
Diabetes  □ Ja □ Nei □ Vet ikke Dersom ja, tar du medisiner for det? ____ 
Høyt blodtrykk □ Ja □ Nei □ Vet ikke Dersom ja, tar du medisiner for det? ____ 
Høyt kolesterol □ Ja □ Nei □ Vet ikke Dersom ja, tar du medisiner for det? ____ 
Høye triglyserider □ Ja □ Nei □ Vet ikke Dersom ja, tar du medisiner for det? ____ 
Andre sykdommer □ Ja □ Nei □ Vet ikke Dersom ja, tar du medisiner for det? ____ 
        (Evt. kan du sjekke?) 
 
   
 
ID:____________ 
 
Har du hatt: 
Operasjon de siste 3 mnd?   □ Ja  □ Nei 
Vektøkning/- reduksjon de siste 6 mnd? □ Ja  □ Nei  
Dersom ja, hvor mye?   __________________  
 
 
Tar du vitamin tilskudd? □ Ja □ Nei □ Vet ikke Dersom ja, hvilke? __________________ 
Tar du tran eller omega 3? □ Ja □ Nei □ Vet ikke Dersom ja, hvilke? __________________ 
 
Vil det være OK for deg og ikke ta vitaminer, tran el omega 3 tilskudd i 5 mnd? 
 □ Ja   □ Nei  □ Vet ikke 
 
 
Allergi eller intoleranse? □ Ja □ Nei        
Røyker?   □ Ja □ Nei        
Snus?    □ Ja □ Nei Dersom ja, hvor ofte?     
Alkohol?   □ Ja □ Nei        
 Gjennomsnittlig inntak og hvor ofte?         
 
Vil det være OK for deg og ikke drikke vin, øl eller annen alkohol i 2 perioder på 5 uker? 
 □ Ja  □ Nei 
 
 
Vil det være OK for deg å unngå følgende matvarer i 4 uker? 
Melk     □ Ja □ Nei       
Ost     □ Ja □ Nei       
Yoghurt    □ Ja □ Nei       
Is/ yoghurtis    □ Ja □ Nei       
Andre melkeprodukter  □ Ja □ Nei       
(pudding, saus, rømme) 
   
 
ID:____________ 
Egg     □ Ja □ Nei       
Fiskeprodukter   □ Ja □ Nei       
Kjøttprodukter (kylling, biff, svin) □ Ja □ Nei       
 
 
Har du deltatt i forskningsprosjekter de siste 3 måneder? □ Ja □ Nei  
Dersom ja, hvilken?        
 
Kan du tenke deg å ha navnet ditt i en ”navne bank” for fremtidige forskningsprosjekter ved NIFES? 
□ Ja  □ Nei  
 
 
Hvordan vil du bli kontaktet? ________________________________________________________ 
 
 
Kommentarer ____________________________________________________________________ 
  ____________________________________________________________________ 
  ____________________________________________________________________ 
____________________________________________________________________ 
  ____________________________________________________________________ 
 
 
 
 
Skjema er utarbeidet etter mal fra og i samarbeid med Laval Universitet, Canada 
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 ID: ___________________ 
Dato: _________________ 
 
BAKGRUNN OG MATHISTORISK SPØRRESKJEMA  
I dette spørreskjemaet ber vi deg ha fokus på ulike aspekter ved din helse og dine matvaner. 
Sett kryss ved ditt svar alternativ. 
 
All besvarelser er viktig for forskningen, men du kan selv velge å besvare undersøkelsen fullstendig 
eller bare deler av den. Dine svar vil være konfidensielle. 
 
1. Hvilket kjønn er du? □ Kvinne  □ Mann 
 
2. Når er du født?  ___/___/_____ 
 
3. Hvor mye veier du nå?  
_________ kg 
4. Hva var din vekt da du var 25 år? 
ca. _________ kg 
Dersom du ennå ikke har fylt 25 år, ikke besvar dette spørsmålet.  
 
5. Har du gått ned eller opp i vekt de siste 6 månedene? 
□ Ned   
□ Opp   
□ Nei, min kroppsvekt er stabil (gå til spørsmål 7)  
□ Vet ikke (gå til spørsmål 7) 
 
6. Dersom du har gått ned/opp i vekt de siste 6 månedene, spesifiser hvor mye:   
□ 0 - 2 kg 
□ 2.1 - 5 kg 
□ 5.1 - 7 kg 
□ 7.1 - 10 kg 
□ Mer enn 10 kg 
□ Vet ikke 
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ID: _________________ 
 
7. Planlegger du å gå ned i vekt de kommende månedene? 
□ Ja 
□ Nei 
□ Vet ikke 
 
 
8. Lider du av en av de følgende sykdommer, eller har du fått utført større operasjoner? 
Kryss av for det som gjelder deg: 
Ja Nei Vet ikke Hvis Ja, spesifiser Alder ved diagnose 
Diabetes type 1 □  □ □  _______________ _________________ 
(insulinavhengig) 
Diabetes type 2 □  □ □  _______________ _________________ 
(livsstilsdiabetes) 
Hjerte-karsykdom □  □ □  _______________ _________________ 
(f.eks. hjerteinfarkt, angina, bypass, slag) 
 
Høyt blodtrykk  □  □ □  _______________ _________________ 
Høyt kolesterol □  □ □  _______________ _________________ 
Høyt triglyseridnivå □  □ □  _______________ _________________ 
Stoffskiftesykdom □  □ □  _______________ _________________ 
Mage- tarmsykdom    □  □ □  _______________ _________________ 
Leversykdom      □  □ □  _______________ _________________ 
Nyresykdom   □  □ □  _______________ _________________ 
Kreft   □  □ □  _______________ _________________ 
Kirurgi (tidligere  □  □ □  _______________ _________________ 
eller planlagt)  
Annet   □  Spesifiser _________________________________________________ 
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ID: _________________ 
 
9. Reseptbelagte medisiner 
 
Tar du noen medisiner nå? □ Ja   □ Nei 
 
Medisin navn Dose (oppgi str.) Hyppighet Symtomer  Start dato Slutt dato 
 
___________ ______________ _________ ______________ ___/___/___ ___/___/___ 
___________ ______________ _________ ______________ ___/___/___ ___/___/___ 
___________ ______________ _________ ______________ ___/___/___ ___/___/___ 
___________ ______________ _________ ______________ ___/___/___ ___/___/___ 
___________ ______________ _________ ______________ ___/___/___ ___/___/___ 
___________ ______________ _________ ______________ ___/___/___ ___/___/___ 
___________ ______________ _________ ______________ ___/___/___ ___/___/___ 
 
Dersom du tar medisiner for å kontrollere ditt kolesterol, vil du være i stand til å avslutte behandlingen minst 
6 uker før start av studien, med tillatelse fra din lege?                                    
□ Ja  □ Nei □ Ikke aktuelt 
 
Har du noen former for allergi mot medisiner? 
□ Ja  Hvis Ja, spesifiser: ____________________ 
□ Nei 
 
 
10. Helsekostprodukter 
 
Har du de siste 3 månedene brukt noen helsekostprodukter (kosttilskudd, vitaminer/mineraler, homøopatisk 
produkter, probiotisk, urtemedisiner, omega-3 kapsler, naturlegemidler)? 
□ Ja  □ Nei 
  
Produkt navn  Dose (oppgi stk.)   Hyppighet Start mnd/år Slutt mnd/år 
 
_______________ ____________ _________ ____/____ ____/____ 
_______________ ____________ _________ ____/____ ____/____ 
_______________ ____________ _________ ____/____ ____/____ 
_______________ ____________ _________ ____/____ ____/____ 
_______________ ____________ _________ ____/____ ____/____ 
_______________ ____________ _________ ____/____ ____/____ 
 
Dersom du benytter noen helsekostprodukter, er det ok for deg å slutte med disse minst 6 uker før start av 
studien? 
□ Ja  □ Nei □ Ikke aktuelt 
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ID: _________________ 
 
11. Bruker du eller har du jevnlig brukt tobakk (sigaretter, snus)? 
□ Ja 
□ Nei 
Hvis Ja, hvor mange ganger daglig? _______________________ 
 
Dersom du har sluttet å bruke tobakk, oppgi mnd/ år for sluttdato: _____________ 
 
 
 
12. Bruker du eller har du jevnlig brukt alkohol? 
□ Ja 
□ Nei 
Hvis Ja, type alkohol? _____________________________________________  
_______________________________________________ 
Hvor mange ganger i uken? _______________________________ 
Enheter konsumert hver gang? ____________________________ 
(1 enhet = 1 øl, 1 glass vin, 1 liten drink) 
 
Dersom du har sluttet å bruke alkohol, oppgi mnd/ år for sluttdato: _________________ 
 
 
 
13. Bruker du eller har du jevnlig brukt narkotiske stoffer? 
□ Ja 
□ Nei 
Hvis Ja, type narkotiske stoffer? _________________________________________ 
     _________________________________________ 
Hvor mange ganger i uken? ________________________________ 
Mengde konsumert hver gang? _____________________________ 
 
Dersom du har sluttet å bruke narkotiske stoffer, oppgi mnd/ år for sluttdato: _____________ 
 
 
 
14. Er du i fysisk aktivitet (inkludert gå/sykle til jobb, søndagstur, lagtrening, helsestudio, osv.)? 
□ Ja   □ Nei 
 
Type aktivitet            Hyppighet            Varighet 
____________________     _________/uke         ____ (timer): _____ (minutter) 
____________________     _________/uke         ____ (timer): _____ (minutter) 
____________________     _________/uke         ____ (timer): _____ (minutter) 
____________________     _________/uke         ____ (timer): _____ (minutter) 
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ID: _________________ 
 
15. Solvaner 
 
A. Hvor ofte bruker du solarium?  
□ 1-2 ganger i uken        
□ 2-3 ganger i mnd      
□ 1 gang i mnd     
□ Sjeldnere enn 1gang i mnd     
□ Aldri 
 
B. Hvor mange uker de tre siste månedene har du vært på badeferie (Norge eller Syden)? 
□ 7 uker eller mer          
□ 4-6 uker          
□ 2-3 uker        
□ 1 uke        
□ Har ikke vært på badeferie 
 
C. Hvor mye utendørsaktivitet har du om sommeren (turer, hagearbeid, jobb)? 
□ Ute nesten hele tiden         
□ Ganske mye          
□ Middels       
□ Lite 
 
 
Sjømatinntak 
 
16. Hvor ofte bruker du fisk, fiskeprodukter eller annen sjømat som middagsmat? 
 
□ Mer enn 5 ganger /uke 
□ 3 ganger eller mer / uke 
□ 1-2 ganger / uke 
□ 1-3 ganger / måned 
□ Sjeldnere enn 1 gang / måned 
□ Aldri  
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ID: _________________ 
 
17. Hvis du spiser fisk, fiskeprodukter eller annen sjømat til middag, hvor mye spiser du vanligvis?  
(1 porsjon = 150 gram, tilsvarer for eksempel 1 laksekotelett eller 3 fiskekaker eller 2 dl reker u/skall) 
□ 1/2 porsjon eller mindre 
□ 1 porsjon 
□ 1 ½ porsjon 
□ 2 porsjoner 
□ 3 porsjoner 
 
 
 
18. Hvor ofte bruker du sjømat som pålegg, i salat, mellommåltid, snacks eller lignende? 
 
□ Mer enn 5 ganger /uke 
□ 3 - 5 ganger eller mer / uke 
□ 1-2 ganger / uke 
□ 1-3 ganger / måned 
□ Sjeldnere enn 1 gang / måned 
□ Aldri  
 
 
 
19. Hvis du bruker sjømat som pålegg, i salat, mellommåltid, snacks eller lignende, beskriv hvor mye 
du vanligvis spiser? 
(for eksempel boks makrell i tomat, antall fiskekaker, dl reker til antall brødskiver/knekkebrød) 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
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ID: _________________ 
 
20. Hvor ofte spiser du vanligvis følgende sjømat som middag? 
 
3 ganger eller 
mer/uke 
1-2 
ganger/uke 
1-3 ganger 
/mnd 
Sjeldnere enn 
1 gang/mnd Aldri 
Laks, ørret □ □ □ □ □ 
Makrell □ □ □ □ □ 
Sild □ □ □ □ □ 
Kveite □ □ □ □ □ 
Uer □ □ □ □ □ 
Steinbit □ □ □ □ □ 
Flyndre, rødspette □ □ □ □ □ 
Torsk □ □ □ □ □ 
Sei □ □ □ □ □ 
Hyse □ □ □ □ □ 
Abbor, gjedde 
(ferskvann) □ □ □ □ □ 
Røye, sik (ferskvann) □ □ □ □ □ 
Reker □ □ □ □ □ 
Krabbe □ □ □ □ □ 
Hummer □ □ □ □ □ 
Blåskjell □ □ □ □ □ 
Kamskjell □ □ □ □ □ 
Fiskekaker □ □ □ □ □ 
Fiskeboller □ □ □ □ □ 
Fiskepudding □ □ □ □ □ 
Fiskegrateng □ □ □ □ □ 
Fiskepinner □ □ □ □ □ 
Fiskesuppe □ □ □ □ □ 
Klippfisk □ □ □ □ □ 
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ID: _________________ 
 
21. Hvor ofte spiser du vanligvis følgende sjømat som pålegg? 
 
 3 ganger eller 
mer/uke 
1-2 
ganger/uke 
1-3 ganger 
/mnd 
Sjeldnere enn 
1 gang/mnd 
Aldri 
Makrell i tomat □ □ □ □ □ 
Sardin på boks □ □ □ □ □ 
Brisling □ □ □ □ □ 
Ansjos □ □ □ □ □ 
Røkt laks, ørret □ □ □ □ □ 
Gravet laks, ørret □ □ □ □ □ 
Tunfisk på boks □ □ □ □ □ 
Sild (sursild, 
rømmesild, 
kryddersild el.lign.) 
□ □ □ □ □ 
Kaviar □ □ □ □ □ 
Crabsticks □ □ □ □ □ 
Svolværpostei □ □ □ □ □ 
Lofotpostei □ □ □ □ □ 
Annet sjømat 
(spesifiser): □ □ □ □ □ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
 
 
22. Spiser du innmat av fisk? 
□ Ja  □ Nei 
Dersom ja, hvor mange ganger per år spiser du fiskeinnmat? 
 1-3 ganger/år 4-6 ganger/år 7-9 ganger/år ≥ 10 ganger/år 
Rogn □ □ □ □ 
Fiskelever □ □ □ □ 
  
ID: ____________ 
 
 
23. Har du noen former for matallergi? 
□ Ja  Hvis Ja, spesifiser: ___________________________________________ 
□ Nei 
□ Vet ikke 
 
 
24. Har du noen former for matintoleranse? 
□ Ja  Hvis Ja, spesifiser: ___________________________________________ 
□ Nei 
□ Vet ikke 
 
 
25. Har du bestemte spisevaner (f.eks vegetar, lav-karbo, religiøse tilpasninger, osv.)? 
□ Ja  Hvis Ja, spesifiser: ___________________________________________ 
□ Nei 
□ Vet ikke 
 
 
26. Bruker du vektreduserende produkter (f.eks. Nutrilett, Allévo) 
□ Ja  Hvis Ja, spesifiser: ___________________________________________ 
□ Nei 
□ Vet ikke 
 
 
 
27. Hvor mange måltider spiser du daglig? ________ stk 
 
 
 
28. Hvor mange mellommåltider spiser du daglig? ________ stk 
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ID: ____________ 
 
29. Generelt, hvem lager måltidene hjemme hos deg? (Sett kun ett kryss) 
□ Jeg 
□ Min ektefelle/samboer 
□ Begge 
□ Annet familiemedlem 
□ Jeg spiser som oftes ferdigmat (f.eks. Fjordland eller tilsvarende) 
□ Jeg ønsker ikke å svare 
 
 
 
30. Spiser du på restaurant (inkludert gatekjøkken, kafé, hamburgerrestaurant, osv)? 
□ Ja  Hvis Ja, hvor ofte? ___________________ 
□ Nei 
 
 
 
31. Spiser du vanligvis måltidene sammen med andre personer (venner, ektefelle, familie, osv)? 
□ Ja 
□ Nei 
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ID: ____________ 
 
Utenom deg selv, har andre i din familie hatt eller har en av følgende sykdommer:     
 
32. Familiehistorie  
Dersom Ja, spesifiser: F = far, M = mor, B = bror, S = søster, G = besteforeldre, U = ukjent (f.eks.adoptert) 
 
     Ja Nei Vet ikke Hvis Ja, spesifiser hvem: 
Diabetes type 1   □  □ □  _______________________ 
(insulinavhengig) 
Diabetes type 2   □  □ □  _______________________ 
(livsstilsdiabetes) 
Hjerte-karsykdom   □  □ □  _______________________ 
(f.eks. hjerteinfarkt, angina, bypass, slag) 
Høyt blodtrykk    □  □ □  _______________________ 
Høyt kolesterol   □  □ □  _______________________ 
Høyt triglyseridnivå   □  □ □  _______________________ 
Stoffskiftesykdom   □  □ □  _______________________ 
Kreft     □  □ □  _______________________ 
Annet     □  □ □  _______________________ 
 
 
De neste spørsmålene (spm. 33-45) er ment kun for kvinner: 
33. Ved hvilken alder hadde du din første menstruasjon? 
__________________ år □ Vet ikke 
 
 
34. Planlegger du å bli gravid: 
□ Ja 
□ Nei 
□ Vet ikke 
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ID: ____________ 
 
35. Bruker du hormonprevensjon? 
□ Ja  □ Nei 
Hvis ja, hvilke? □ Tabletter (p-pille)  Spesifiser produktnavn:________________ 
   □ Hormonspiral  Spesifiser produktnavn:________________ 
   □ P-plaster   Spesifiser produktnavn:________________ 
   □ P-implantat  Spesifiser produktnavn:________________ 
   □ Annet, spesifiser __________________________________________ 
 
36. Er du i overgangsalderen (12 mnd siden siste menstruasjon)?   
□ Ja (hvis Ja, besvar spørsmålene 37 til 40) 
□ Nei (gå til spørsmål 41) 
□ Vet ikke (gå til spørsmål 41)  
 
 
37. Alder for overgangsalder:   
____________ år gammel  □ Vet ikke 
 
38. Type overgangsalder:   
□ Naturlig 
□ Fjerning av livmor 
□ Delvis fjerning av livmor og én eggstokk     
□ Delvis fjerning av livmor og begge eggstokker 
□ Kvinnelig sterilisering 
□ Fremprovosert av kreftbehandling eller annen medisinsk behandling    
□ Vet ikke  
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ID: ____________ 
 
39. Tar du hormonerstatninger nå for tiden?    
□ Ja 
□ Nei 
 
Hvis Ja, startdato: ___ / ___ / ___ 
Hvis Ja, type hormoner: _________________________________________________________ 
 
 
40. Har du tidligere vært behandlet med hormonerstatning?     
□ Ja 
□ Nei 
 
Hvis Ja, slutt dato: ___ / ___ / ___ 
Hvis Ja, type hormoner: _________________________________________________________ 
 
 
41. Antall graviditeter (inkludert spontanaborter og aborter): 
__________________ □ Ikke aktuelt 
 
42. Har du noen ganger hatt diagnosen diabetes under graviditet (svangerskapsdiabetes)?   
□ Ja (hvis Ja, besvar spørsmål 43-45) 
□ Nei 
□ Ikke aktuelt 
 
 
43. Har du vært under medisinsk oppfølging grunnet din diabetes under graviditet?   
□ Ja 
□ Nei 
□ Ikke aktuelt 
 
Hvis Ja, spesifiser hvilken graviditet? ______________ 
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ID: ____________ 
 
44. Har du fått kostveiledning grunnet din diabetes under graviditet? 
□ Ja 
□ Nei 
□ Ikke aktuelt 
 
Hvis Ja, spesifiser hvilken graviditet? ______________ 
 
 
45. Har du tatt medisiner grunnet din diabetes under graviditet?    
□ Ja 
□ Nei 
□ Ikke aktuelt 
 
Hvis Ja, spesifiser hvilken graviditet? ______________ 
Hvis Ja, type medisin (insulin eller annet) ______________ 
 
 
Takk for innsatsen med besvarelsen! 
 
 
 
 
Spørreskjema er utarbeidet etter mal fra og i samarbeid med Laval Universitet, Canada 
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